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3 ABSTRACT
Factor V Leiden (FV Leiden) is the most common inherited thrombophilia in 
Caucasians increasing the risk for venous thrombosis 5-fold. FV Leiden has also 
been associated with several pregnancy complications. However, the magnitude 
of risk for pregnancy-associated venous thrombosis needs to be more accurately 
defined and the impact of FV Leiden on specific pregnancy complications is 
unclear.
The main aim of the study was to assess FV Leiden as a risk factor for pregnancy 
complications in which prothrombotic mechanisms may play a part. Specifically, 
the study aimed to assess the magnitude of the risk, if any, associated with FV 
Leiden for pregnancy-associated venous thrombosis, pre-eclampsia, unexplained 
stillbirth, and preterm birth.
The study was conducted as a nested case-control study within a fixed cohort of 
100,000 consecutive pregnant women in Finland. The study was approved by the 
ethics committee of the Finnish Red Cross Blood Service and by the Ministry of 
Social Affairs and Health. All participants gave written informed consent.
In Finland, practically all pregnant women contact their local Maternity Welfare 
Clinic during the 8th to 12th week of pregnancy. At the first visit, samples are 
taken for blood group serology tests, which are performed in the Finnish Red 
Cross Blood Service at the department of antenatal serology. The department 
maintains the National Register of Blood Groups and Blood Group Antibodies of 
Pregnant Women from which data for 100,000 consecutive pregnant women were 
obtained. Only the first pregnancy of each woman after January 1st, 1997 was 
included in the cohort. The National Institute for Health and Welfare maintains 
the National Hospital Discharge Register with diagnoses classified according to 
the International Classification of Diseases (ICD-10 since 1996). Personal unique 
identification codes were used to link the two registers to obtain diagnoses for 
the 100,000 consecutive pregnant women. 
The case-candidates and control-candidates who fulfilled the invitation criteria 
(alive, mother tongue Finnish or Swedish, residence in Finland) were invited by 
letters and reminders. Participants gave blood samples for DNA tests and filled 
out questionnaires to supplement clinical data gathered from medical records. 
The medical records of participants were reviewed in 49 maternity hospitals 
in Finland. All data were collected on standardized forms blinded to laboratory 
results. Genomic DNA was isolated from blood samples and genotyping was 
performed in the Finnish Genome Center. Genotyping of seven polymorphisms, 
including FV Leiden, was based on restriction enzyme digestions after PCR. 
When evaluating pregnancy-associated venous thrombosis, 34 cases and 641 
controls were assessed. In all, FV Leiden was associated with an 11-fold risk 
(OR 11.6, 95% CI 3.6-33.6). When analyzing only cases with the first venous 
thrombosis, FV Leiden was associated with a 6-fold risk (OR 5.8, 95% CI 1.6-
21.8). The risk was modified by blood group, body mass index (BMI), and age. 
In women with FV Leiden and non-O blood group, the risk was 25-fold compared 
with women without these characteristics. In women with FV Leiden and BMI 
over 30 kg/m2, the risk was 75-fold compared with women without the mutation 
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and BMI less than 25 kg/m2. In women with FV Leiden and age over 35 years, 
the risk was nearly 60-fold compared with women without the mutation and age 
less than 25 years. In the whole study population, 19% of thromboses were 
attributable to FV Leiden.
When evaluating pre-eclampsia, 248 cases and 679 controls were assessed. In 
all, FV Leiden was associated with a trend of increased risk for pre-eclampsia 
(OR 1.7, 95% CI 0.8-3.9). The point estimates of the risk in subgroups of 
pre-eclampsia were 1.5-2.5 when all women were analyzed and 2.4-3.4 when 
primigravid women were considered. However, these associations were not 
statistically significant.
When evaluating unexplained stillbirth, 44 cases and 776 controls were assessed. 
In all, FV Leiden was associated with over a 3-fold risk (OR 3.8, 95% CI 1.2-
11.6). FV Leiden was especially associated with late unexplained stillbirth with 
about a 4-fold risk in both all and singleton pregnancies.
When evaluating preterm birth, 324 cases and 752 controls were assessed. In 
all, FV Leiden was associated with over a 2-fold risk (OR 2.4, 95% CI 1.3-4.6). 
FV Leiden was especially associated with late preterm birth with about a 3-fold 
risk, but not with early preterm birth. The association was significant also when 
primigravid cases and controls were analyzed (OR 3.3) and when cases and 
controls without stillbirth, pre-eclampsia, intrauterine growth restriction (IUGR), 
placental abruption, or chorionamnionitis were analyzed (OR 2.6).
This large population-based nested case-control study on ethnically homogeneous 
women showed FV Leiden to be a clear risk factor for many pregnancy 
complications. Results were partly confirmatory and partly novel. New information 
was gained especially on preterm birth and unexplained stillbirth. The results 
suggest that FV Leiden interacts with common risk factors especially in venous 
thrombosis. In all, maternal carriage of FV Leiden was associated with an 11-fold 
risk for pregnancy-associated deep venous thrombosis, a 1.7-fold risk for pre-
eclampsia, a 3-fold risk for unexplained stillbirth, and a more than 2-fold risk for 
preterm birth. The results can be generalized to Finnish women with pregnancies 
continuing beyond first trimester and may be applied to Caucasian women in 




Thrombophilia means predisposition to thrombosis, i.e., an increased tendency to 
have blood clots in veins or arteries. Thrombophilia may be inherited or acquired. 
A point mutation in a coagulation factor V (F V) gene (G1691A), named factor 
V Leiden (FV Leiden), is the most common known inherited thrombophilia in 
Caucasians [1]. Due to this mutation, activated F V (F Va) and F V are improperly 
cleaved and neutralized by activated protein C (APC). This phenomenon is named 
APC resistance and it leads to enhanced production of thrombin. It is generally 
accepted that FV Leiden increases the risk for venous thrombosis [2]. However, 
the extent of the risk in pregnancy-associated venous thrombosis needs to be 
defined more precisely, considering that pregnancy itself is a hypercoagulable 
state.
Thrombophilia has been associated, not only with venous thrombosis, but also 
with many specific pregnancy complications. Normal placental function is vital for 
fetal wellbeing. It has been hypothesized that thrombophilia may increase the risk 
for placenta-mediated pregnancy complications (pregnancy loss, pre-eclampsia, 
IUGR, placental abruption) by two mechanisms: first, by causing placental 
insufficiency due to placental micro- or macro-vascular thrombosis, and second, 
by effects on trophoblast cells [3,4]. Inflammatory mechanisms play an important 
role in both normal and complicated pregnancies [5]. Abnormal immunological 
balance may lead to pregnancy complications, such as pre-eclampsia and preterm 
birth [5]. Because of extensive interaction between coagulation and inflammation 
[6], a third mechanism by which thrombophilia might increase the risk could 
be through potentiating inflammatory responses. The impact of thrombophilia 
– including FV Leiden – on specific pregnancy complications is unclear because of 
conflicting results from mostly small and heterogeneous studies.
Screening for thrombophilia has been under debate since the first findings of 
association between thrombophilia and pregnancy complications. However, 
before screening is indicated, a risk factor has to be reliably identified, risk 
associated with the risk factor should be substantial, and the result of screening 
should influence treatment [7]. Well-planned epidemiological studies can provide 
valuable information on the association between a risk factor and disease, in this 
case, between thrombophilia and pregnancy complications. Nested case-control 
study design, a variation of cohort study, has the advantages of a cohort study 
and is more feasible as only cases and a sample of controls in a fixed cohort are 
studied in detail [8].
In Finland, conditions for population-based studies are good due to high-quality 
administrative national registers (e.g., the Hospital Discharge Register) and 
a possibility to link data from different registers by using unique identification 
codes. Finland has a comprehensive free prenatal care system ensuring that 
pregnancy complications are diagnosed early and treated properly. Practically all 
pregnant women contact the Maternity Welfare Clinic during the first trimester of 
pregnancy and are thereby registered in the National Register of Blood Groups 
and Blood Group Antibodies of Pregnant Women kept by the Finnish Red Cross 
Blood Service. The Finnish population is ethnically homogeneous which enables 
the unconfounded assessment of genetic risk factors that are of Caucasian origin.
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The importance of FV Leiden as a risk factor for pregnancy complications 
clearly needs further investigation. In this population-based nested case-control 
study, FV Leiden was assessed as a risk factor for pregnancy-related venous 
thrombosis, pre-eclampsia, stillbirth, and preterm birth in a large cohort of 
100,000 consecutive pregnant Finnish women. Cases and controls were identified 
by linking national registers. Information gathered from the questionnaires 
and medical records of participants made it possible to ensure the accuracy of 
register-based diagnoses and to analyze clinical subgroups.
4 INTRODUCTION
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5.1 Hemostasis
The main factors maintaining the balance between bleeding and thrombosis are 
the vessel wall, platelets, coagulation system, and fibrinolytic system.
At the site of a vessel wall injury, platelets serve as the first hemostatic plug 
by adhering to exposed collagen directly and through von Willebrand factor. 
Aggregated and activated platelets support local coagulation by providing a 
negatively charged phospholipid surface for the coagulation cascade, which 
eventually forms a stable fibrin clot. Coagulation is regulated by natural 
anticoagulant mechanisms to limit the process at the site of injury. Finally, the 
clot is dissolved by the fibrinolytic system. [9]
5.1.1 Coagulation cascade
Figure 1 presents a sketch of the coagulation cascade. The procoagulant 
coagulation cascade is composed of serine protease enzymes and their 
cofactors. The end point of this cascade is the formation of active thrombin. The 
coagulation cascade occurs on a phospholipid surface, mainly on the activated 
platelets or the injured endothelium, in the presence of Ca++. The coagulation 
process begins when tissue factor (TF) is exposed to blood and binds with F 
VIIa, which pre-exists in trace amounts in the blood. F VIIa needs to be bound 
to TF to gain proteolytic activity. TF - F VIIa complex activates F IX and more 
efficiently F X. [10] The first small amounts of F Xa activate F V, and together 
they form a prothrombinase complex to activate prothrombin to thrombin [11]. 
After this initiation phase, the newly formed thrombin activates F V, F VIII, 
and F XI, thereby accelerating its own activation and leading to a very efficient 
propagation phase of coagulation. F IXa, with its now activated cofactor F VIIIa 
(tenase complex), activates efficiently F X, and then F Xa, with its cofactor F 
Va (prothrombinase complex), activates prothrombin to thrombin. F XIa serves 
as another activator for F IX to ensure the efficiency of the thrombin formation 
process. [10] Thrombin converts the soluble fibrinogen into insoluble fibrin, which 
forms a network in and around the platelet plug. Thrombin also activates F XIII, 
which cross-links fibrin molecules to form a stable clot. [9] In addition, thrombin 
further activates platelets [10], ensuring excellent conditions for coagulation to 
proceed on the phospholipid surface.
As a link between coagulation and inflammation, thrombin can activate 
endothelial cells, mononuclear cells, platelets, fibroblasts, and smooth muscle 
cells through PAR-1, PAR-3, and PAR-4 (protease activated reseptors) on their 
surface, leading to the production of several cytokines and growth factors [6].
Anticoagulant mechanisms regulate the coagulation cascade rigorously to limit 
thrombosis at the site of vessel wall trauma. Limiting factors include several 
phenomena: adhered, activated platelets remain at the site of injury, serine 
proteases involved in the process need to be proteolytically activated, and 
physiologic anticoagulants – tissue factor pathway inhibitor (TFPI), antithrombin, 
and the protein C system – control critical points of the coagulation cascade [10]. 
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Platelet factor 4 released from platelets increases protein C activation rate and 
this may also limit thrombus formation outside the site of injury [12].
TFPI neutralizes stoichiometrically the TF - F VII complex [10]. Antithrombin 
can neutralize all the procoagulant serine proteases by binding to them [10], 
the primary targets being thrombin, F Xa, and F IXa [13]. The protein C system 
regulates the coagulation process dynamically by responding to the presence of 
thrombin. This anticoagulant system is described in detail in the next section.
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Figure 1. Coagulation cascade.
5.1.2 Protein C anticoagulant pathway
After thrombin is formed, it down-regulates its own formation through the 
thrombin-thrombomodulin-protein C system [10]. When thrombin binds to 
thrombomodulin present on the surface of the intact endothelium, it loses its 
procoagulant activity. Thrombomodulin-bound thrombin is not only efficiently 
inactivated by antithrombin and other inhibitors, but it also activates protein C 
to activated protein C (APC) [12]. Endothelial cell protein C receptor (EPCR), also 
present on the endothelium, presents protein C to the thrombin-thrombomodulin 
complex enhancing protein C activation [12].
14
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APC, with its cofactor protein S, inactivates F Va and F V IIIa by cleaving certain 
peptide bonds in them. F Va is cleaved at least at the sites R306, R506, and 
R679 and F VIIIa at the sites R336 and R562 [14]. This inactivation of central 
factors in the propagation phase of the coagulation cascade efficiently reduces 
the formation of thrombin and eventually also the formation of APC. APC is slowly 
inactivated by protein C inhibitor and alfa-1 antitrypsin [14].
The thrombin-thrombomodulin complex efficiently activates also thrombin 
activatable fibrinolysis inhibitor (TAFI), which renders fibrin clot more resistant 
to lysis [13]. The protein C pathway is also involved in limiting inflammatory 
responses [6,12].
Figure 2. Protein C anticoagulant pathway.
5.1.3 Factor V
Factor V (F V), which was discovered by Paul Owren in 1943 [15], has proved to 
be an important regulator of the hemostatic balance with both procoagulant and 
anticoagulant properties [14]. 
The gene of F V is on the chromosome 1 (1q23), and this single-chained 
glycoprotein of 2,196 amino acids is synthesized in the liver. Of the total F V, 
20% is stored in platelet α-granules, the rest circulates in plasma [11]. The F V 
in platelets is of plasma origin, but it is already modified in platelets by partial 
proteolysis, giving it considerable F Xa-cofactor activity [11]. This seems to be 
an efficient way to ensure that this important factor is immediately present at the 
site of vessel wall injury and ready to function. 
F V is activated by F Xa or thrombin to F Va by the cleavage of three peptide 
bonds (Arg709, Arg1018, Arg1545) [11]. The inactivation of F Va is mediated 
through APC, which cleaves the F Va at the sites Arg506, Arg306, and Arg679, 
15
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usually in this order [14]. The Arg506 is the preferred site for proteolysis, but 
protected by F Xa in prothrombinase complex when coagulation is in process. 
However, protein S accelerates the slower proteolysis at the site Arg306 [16] and 
helps APC to reach the Arg506 site [13]. After cleavage at the site Arg506, F Va 
still has partial procoagulant activity, which is abolished when the Arg306 and 
Arg679 peptide bonds are cleaved [17].
F V has procoagulant as well as anticoagulant properties. In its activated form, F 
Va serves as an essential cofactor for F Xa (the prothrombinase complex) in the 
formation of thrombin [11]. On the other hand, the intact F V acts as a cofactor 
in the protein C system by stimulating the cofactor activity of protein S in the 
inactivation of F VIIIa by APC [18]. This anticoagulant activity appears after the 
cleavage of a peptide bond at the Arg506 by APC [14]. Mutations in the F V gene 
may lead to hemorrhagic and thrombotic tendencies.
5.2 Pregnancy and hemostasis
Many adjustments and adaptations happen in a woman during pregnancy. 
In the blood, the most important alterations during normal pregnancy are 
increased plasma volume, physiologic decrease of hemoglobin, occasional mild 
thrombocytopenia, neutrophilia, increases in many procoagulant factors, and 
attenuated fibrinolysis [19]. 
Increases in many coagulation factor levels, decrease of anticoagulant activity, 
and diminished fibrinolysis lead to a hypercoagulable state protecting from 
excessive bleeding during delivery. The most prominent changes are a decrease 
in protein S activity (due to the increase of C4BP); acquired protein C resistance; 
increased levels of von Willebrand factor, F VIII, and F VII; increased fibrinogen; 
and increased activity of fibrinolytic inhibitors (TAFI, PAI-1, PAI-2). Usually the 
levels of F II, F V, F IX, and F X increase slightly and the level of F XI decreases 
slightly.  [19-22] F XIII level increases early in the pregnancy but decreases 
thereafter [20]. Coagulation parameters usually reach their baseline levels by 
eight weeks postpartum [19].
5.3 Factor V Leiden
5.3.1 History
In 1993, Dahlbäck et al. in Malmö, Sweden described a new phenomenon, i.e., 
poor anticoagulant response to activated protein C, in a family with a history of 
venous thromboses. The phenomenon was thought to be due to the deficiency 
of a new protein C cofactor and the laboratory phenomenon was named APC 
resistance [23]. In May 1993, a commercial APC resistance test became 
available.
APC resistance was quickly demonstrated to be a common risk factor for venous 
thrombosis. In the Leiden Thrombophilia Study (LETS), APC resistance was 
present in 21% of venous thrombosis patients and in 3 % of controls [24]. In 
a Swedish material, about 40% of 104 consecutive venous thrombosis patients 
had APC resistance compared with 7 % of controls [25]. APC resistance was 
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also shown to be present in over 50% of previously unexplained thrombophilic 
patients and concomitantly in a few with a previous diagnosis of protein C or 
protein S deficiency [26].
In early 1994, Dahlbäck et al. reported the cause of APC resistance to be 
a property of factor V [27]. At the same time, Bertina et al. in Leiden, The 
Netherlands also concluded that F V was involved. In June 1994, they published 
a paper showing that a single G to A substitution at the nucleotide position 
1691 in the factor V gene was associated with APC resistance [1]. The point 
mutation causes the replacement of amino acid Arg to Gln at the site 506 in 
factor V resulting in the inadequate inactivation of mutated F Va. The mutation 
was named as factor V Leiden (FV Leiden) [1]. As the site Arg506 is a cleaving 
site for APC, it was now easy to understand why the disappearance of this site 
can cause resistance to APC. Dahlbäck’s initial idea of the lack of a new protein 
C cofactor behind APC resistance has also proved to be partially true as the FV 
Leiden mutation abolishes the cofactor activity of F V in the inactivation of F VIIIa [14].
Dahlbäck and Zöller et al. found FV Leiden mutation in almost all of their fifty 
Swedish APC resistant families proving this mutation to be the most prevalent 
cause for APC resistance [28]. The first large study, LETS, already proved FV 
Leiden to be a frequent risk factor for venous thrombosis [29]. 
5.3.2 Prothrombotic mutation: gain of function – loss of function
FV Leiden is a prothrombotic mutation. It is at the same time a gain-of-function 
mutation and a loss-of-function mutation. First, due to disappearance of the 
cleavage site at the Arg506, APC is unable to inactivate F Va optimally leading 
to increased thrombin formation [17]. Second, due to the disappearance of 
that cleavage site, APC is unable to cleave intact F V so that F V could function 
as cofactor for PC-PS complex in the inactivation of F VIIIa. This loss of 
anticoagulant function leads, again, to increased thrombin formation [14].
However, the risk for venous thrombosis caused by FV Leiden is relatively low. 
This may be explained by the fact that although cleavage at the site Arg506 
accelerates inactivation of F Va remarkably by exposing the cleavage sites Arg306 
and Arg679 to APC, cleavage at the site Arg506 is not absolutely necessary for 
the inactivation of F Va [17]. In addition, in the prothrombinase complex, the 
capability of APC to inactivate F Va is similar for the wild type F Va and F Va 
Leiden, because the Arg506 cleavage site of the wild type F Va is protected by F 
Xa, and in F Va Leiden this cleavage site does not exist. [16,17]. Mechanisms that 
reduce the effect of this potentially injurious mutation include the acceleration of 
the cleavage of F Va by protein S at the site Arg306 [16]. 
5.3.3 Epidemiology and evolutionary advantage
According to haplotype analyses, FV Leiden is a founder mutation, which occurred 
about 21,000 years ago [30-32]. The mutation is present at a variable frequency 
(mean 5%) in Caucasians, but absent or nearly absent in other races [33-35]. 
This indicates that FV Leiden most likely occurred in a Caucasoid subpopulation 
after the separation of non-Africans from Africans, and Caucasoid populations 
from Mongoloid populations [31,33,34]. 
5 REVIEW OF LITERATURE
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The high prevalence of FV Leiden in Caucasians suggests an association with 
evolutionary advantage and many findings support a favourable selection pressure 
[34]. Data exist indicating that FV Leiden might protect against peripartal 
bleeding [36-38] and heavy menstrual blood loss [39]. This could have provided 
considerable advantage by reducing iron depletion and by protecting against life-
threatening post-partum hemorrhage. However, conflicting observations about 
pregnancy-related blood loss exist [40]. Similarly to protecting against excessive 
bleeding in association with surgery [41], FV Leiden may have protected against 
excessive bleeding in association with trauma in the past. Some evidence, 
although partly conflicting, exists that simultaneous carriage of FV Leiden might 
attenuate bleeding symptoms also in hemophiliacs [42].
Other possible selective advantages include a more favourable embryo 
implantation in carriers of FV Leiden [43,44], and an increased fecundity (shorter 
time to pregnancy) in the male carriers of FV Leiden [45]. This is supported by an 
observation of a slightly increased sperm count in the male carriers of FV Leiden [46].
5.4 F II G20210A
Poort et al. reported in 1996 a point mutation in the coagulation factor II 
(prothrombin) gene [47]. The mutation causes a G to A substitution at the 
nucleotide position of 20210 in the 3’-untranslated region of the gene. The point 
mutation is associated with elevated prothrombin levels and is therefore a gain of 
function mutation. FII G20210A allele is associated with about a 2-fold increased 
risk for venous thrombosis [47]. The mutation is of single origin and is mainly 
found in the Caucasian population [32]. 
5.5 Assessment of risk associated with a genetic risk factor
Several different study designs can be used to assess the association between a 
specific genetic risk factor and a disease entity. Each design has its advantages 
and limitations.
In case-control studies, cases are selected on the basis of developing a specific 
disease (outcome). The disease entity should be as homogeneous as possible to 
minimize the risk of any true association remaining unobserved. Controls should 
be from the same population as cases, i.e., if a person without the disease had 
developed the disease, she/he would have been selected as a case. The case-
control design is particularly suitable for rare diseases and it allows many risk 
factors to be evaluated simultaneously. Being less expensive and time-consuming 
than cohort studies, case-control studies are often more feasible. However, 
they are susceptible to selection bias (inclusion of cases or controls is somehow 
dependent of the studied risk factor) and information bias (knowledge of disease 
status, recall bias, reporting bias, research bias, misclassification). Therefore, 
studies should be carefully planned to avoid these biases. Well-planned and 
conducted case-control studies can provide valuable information on the 
association between a risk factor and disease and they can be reliably used to 
test epidemiologic hypothesis. [48] 
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In case of genetic risk factors, case-control studies are efficient and reliable in 
estimating risks if their sizes are in accordance with the prevalence of the studied 
mutation, i.e., if they have enough statistical power [49]. However, false positive 
and false negative associations are possible if the studied population includes 
genetically heterogeneous subgroups [50]. Genetic association studies cannot 
prove causality as the studied genetic marker may only be linked to the causative 
genetic factor.
In cohort studies, individuals are selected on the basis of having or not having an 
exposure or risk factor. Exposed and unexposed individuals are then followed to 
assess the risk for an endpoint or disease. The exposed and unexposed should 
be as similar as possible except for the studied risk factor. The cohort design is 
particularly suitable when the risk factor is rare. Also, it allows assessment of 
many endpoints for a single exposure and direct calculation of endpoint incidence 
rates in the exposed and unexposed. [8]
The best way to establish whether and how much a single mutation alters the risk 
for a specific disease is to study the absolute risk of the disease in carriers and 
non-carriers of the mutation in a fixed population-based cohort over a defined 
time. Prospective cohort studies may have the lowest risk for selection bias as 
the cohort has been identified before the development of the disease. However, 
these studies are seldom feasible as large cohort studies needed for rare diseases 
can be extremely expensive and time-consuming [8]. 
A more feasible variation of a cohort study is a nested case-control study 
in which only cases and a sample of controls in a fixed cohort are assessed in 
detail [8]. In genetic association studies with this design, only cases and controls 
are genotyped for the studied mutation. In this setting, it is possible to study 
relative risks and their ratios and even population parameters that are readily 
generalizable to the known reference population if the sampling is unbiased.
Sometimes the term retrospective study is used as a synonym for a case-control 
study, because in this design researchers have first an outcome for which they 
aim to ascertain a cause. Analogously the term prospective study is sometimes 
used as a synonym for a cohort study, because in this design researches have 
first a suspected risk factor and they follow up a cohort for an outcome. However, 
the terms retrospective and prospective are often used to define whether the 
outcome has occurred before or after the study started. Therefore, case-control 
and cohort studies can be either retrospective or prospective, although this 
distinction is usually used only for cohort studies. [48] 
In all epidemiological studies, it is vital that information has been gathered 
identically from all study subjects. Information about exposure and outcome should 
be accurate and complete [48]. When the information is gathered retrospectively, 
adequate records should be available, and sometimes several sources may 
have to be used [8]. Whether the risk has been assessed in family studies, 
hospital-based studies, registry-based studies, or population-based studies, the 
populations the results can be generalized to must be carefully considered.
In case of thrombophilia, cohorts of carriers (exposed) and non-carriers 
(unexposed) of a mutation are most readily available from thrombophilic 
families. However, population-based studies give more generalizable results. 
In hospital-based studies, cases often represent the most severe cases of the 
specific disease, which may distort the results leading to an overestimation of 
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the risk associated with the mutation. Register-based studies are also used in 
genetic association studies. They are feasible but only as accurate and reliable 
as the information in the registers. Therefore, the validity of diagnoses in the 
register is of great importance [51]. Registers can be used to identify cohorts 
or cases and controls, which then are recruited for the study to give samples 
for DNA. Register-based studies become laborious, but also more accurate, when 
diagnoses and clinical data are checked from the medical records.
As in all research, possible publication-bias should be kept in mind when 
reviewing the literature about genetic risk factors. Publication bias exists when 
researchers, reviewers, or editors submit or accept papers for publication 
depending on the direction or strength of the results [52].
5.6 Venous thromboembolism
Venous thrombosis can be seen as a classic example of complex common 
disease which is caused by interaction of acquired and inherited risk factors [49]. 
Thrombosis occurs when many risk factors are simultaneously present. Each 
risk factor increases the thrombotic potential and eventually a trigger point for 
thrombosis is exceeded. The risk of thrombosis increases with age. Therefore, 
in young adults more risk factors are needed for thrombosis to occur than in old 
age. Among women of fertile-age the incidence of thrombosis is about 1:10,000 
women years. [53]
According to Virchow’s triad from the 1856, the emergence of thrombosis is due 
to changes in the vessel wall, in blood, and in the velocity of blood flow [14]. 
Venous and arterial thromboses only partly share the same risk factors and both 
also have their own risk factors [54].
Thrombophilia can be inherited or acquired. Defects of natural inhibitors of 
coagulation or gain of function of coagulation factors can disturb the strictly 
regulated balance to favour thrombus extension. Antithrombin deficiency, protein 
C deficiency, and protein S deficiency are well known, although rare, inherited 
risk factors for venous thrombosis. They are strong risk factors for venous 
thrombosis, the estimated increase of risk being about 10-fold [2]. Their impact 
on arterial thrombosis, however, is marginal [54].
Gain-of-function mutations, FV Leiden and prothrombin G20210A (FII G20210A), 
are moderate risk factors for venous thrombosis, increasing the risk 5-fold 
and 2- to 3-fold, respectively [2]. They do not have a major impact on arterial 
thrombosis, although in special subgroups of young patients they may be 
involved to some extent [55].
For acquired thrombophilia, antiphopholipid antibodies are of great importance. 
Antiphospholipid antibodies are risk factors for venous and arterial thrombosis as 
well as for pregnancy complications [54].
Non-O blood group is associated with a 2- to 4-fold increased risk for venous 
thrombosis compared with blood group O [2,56]. This is probably due to the 
higher levels of von Willebrand factor (vWF) and F VIII in individuals with these 
blood groups. The lower level of vWF in individuals with blood group O may 
be due to more efficient clearance of vWF, which may be determined by ABH 
antigens on vWF [57].
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The increasing thrombosis risk associated with increasing age may be due to the 
progressive increase of many coagulation factors, impaired function of fibrinolytic 
system, and age-related structural and functional changes in vessel walls [54]. 
Other recognized acquired risk factors for venous thrombosis include obesity, 
previous venous thrombosis, surgery, trauma, immobilization, cancer, oral 
contraceptives, hormone replacement therapy, and pregnancy [54].
5.6.1 Venous thromboembolism in pregnancy
Pregnancy-associated venous thromboembolism is a rare cause of maternal 
morbidity occurring in less than 1 in 1,000 pregnancies in western countries 
[58-62]. In these countries, it is, however, a major cause of maternal mortality 
[58,63-65]. In Finland also, thromboembolism is the main cause of maternal 
deaths [66,67]. 
Pregnancy increases the risk for venous thrombosis 4- to 10-fold. Besides being 
a hypercoagulable state, pregnancy causes venous stasis in lower extremities 
due to the enlarged uterus, and during labour the endothelium of pelvic vessels 
may be damaged. Thromboses in the veins of the left lower extremity are 
overrepresented compared with thromboses occurring in non-pregnant state. 
This may be due to the pronounced compression of the left iliac vein by the right 
iliac artery. Most pregnancy-related venous thromboses occur during pregnancy, 
but the risk for venous thrombosis is higher in postpartum period. [58,63,68]
5.6.2 FV Leiden and venous thromboembolism in pregnancy
Studies that assess the risk associated with FV Leiden for pregnancy-associated 
venous thromboembolism (VTE) vary in many respects. Study designs, selection 
of cases and controls, reporting of ethnicity, definition of puerperium (from 
3 weeks to 3 months postpartum), inclusion of recurrent VTE events, and 
inclusion of homozygotes in analyses differ. Case-control and cohort studies are 
summarized in tables 1 and 2.
In case-control studies (table 1), the odds ratio of pregnancy-associated venous 
thromboembolism for FV Leiden varies from 2.8 to 18.3.
In a meta-analysis published in 2006 by Biron-Andreani et al. [69], a pooled OR 
of six case-control studies was 8.6 (95% CI 5.9-12.6), although these studies 
were found to be heterogeneous. Studies included in this meta-analysis are 
marked with # in the table 1.
In cohort studies (table 2), the odds ratio of pregnancy-associated venous 
thromboembolism for mainly heterozygous FV Leiden varies from 3.7 to 8.3. 
[37,80-84]. For homozygous FV Leiden the OR has been 41.3 [85]. 
In the meta-analysis by Biron-Andreani et al. [69], a pooled OR of cohort 
studies was 4.5 (95% CI 1.8-10.9). This meta-analysis included cohorts from 
thrombophilic families [80,81,83] as well as prospective cohorts of pregnant 
women [37,84]. Studies included in this meta-analysis are marked with # in the 
table 2.
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Prospective population-based cohort studies would give the best estimation 
of the risk associated with FV Leiden in general population. However, the three 
prospective studies available [37,82,84] consist of less than 4,700 mainly White 
women, of whom only 383 are carriers of FVL. Numbers are too small to give a 
definite estimate of risk given that pregnancy-associated venous thrombosis is so 
rare, usually less than 1 per 1,000 pregnancies.
In a systematic review and meta-analysis of Robertson et al. [79], heterozygous 
and homozygous carriers of FV Leiden were analyzed separately for the risk of 
pregnancy-associated venous thrombosis. The pooled OR was 8.3 (95% CI 5.4-
12.7) for heterozygotes, and 34.4 (95% CI 9.9-120) for homozygotes. There 
were no signs of heterogeneity although the eight studies included case-control 
and cohort studies, as well as family studies. Studies included in this meta-
analysis are marked with ¤ in the tables 1 and 2. 
Taken together, FV Leiden has been consistently associated with an increased risk 
for pregnancy-associated venous thrombosis. However, population-based studies 
are still needed to assess the risk in carriers of FV Leiden from the general 
population.
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Table 1. FV Leiden and risk for venous thrombosis associated with pregnancy. Case-control studies.
 Study Country Self-reported 
study design
Study population Cases Controls Venous thrombosis Prevalence of FVL OR (95% CI)
McColl et al.
1997 [59]
UK; Two maternity 
units
Retrospective Ethnicity not reported 50 Population 
prevalence as control
Objectively diagnosed 









Case-control White women 42 213; parous, age-
matched
Objectively diagnosed 








UK; Two maternity 
units















Case-control Ethnicity not reported 119 233; blood donors, 
age-matched, 157 
parous
History of objectively 
diagnosed DVT 
during pregnancy or 
puerperium;
















27 49; matched for 
hospital (and race)
Objectively diagnosed 
VTE during pregnancy 
or puerperium (one 









Case-control Caucasians; women with 
antiphospholipid antibodies 
excluded

































Ethnicity not reported 30 56; age-matched, 
delivery in same 
hospital during same 
fortnight
Objectively diagnosed 





















857; partners of 
cases and a random 
sample
Objectively diagnosed 
VTE in 90% of 
patients
Pregnant cases: 19/100, 
19.0%












Women with 23 completed 
weeks of pregnancy; 
registry-based identification 
of participants; Norwegians
313 (from 18 
hospitals)
353 (from one 
university central 
hospital)
First DVT during 
pregnancy or 
puerperium
Cases: 74/313, 23.6% 
Controls: 23/353, 6.5% 
(figures for heterozygotes)
5.0 (3.1-8.3)
* Calculated from data given in article (StatsDirect).
# Study included in meta-analysis by Biron-Andreani et al. [69].
¤ Study included in meta-analysis by Robertson et al. [79].
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Table 1. FV Leiden and risk for venous thrombosis associated with pregnancy. Case-control studies.
 Study Country Self-reported 
study design
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857; partners of 
cases and a random 
sample
Objectively diagnosed 
VTE in 90% of 
patients
Pregnant cases: 19/100, 
19.0%












Women with 23 completed 
weeks of pregnancy; 
registry-based identification 
of participants; Norwegians
313 (from 18 
hospitals)
353 (from one 
university central 
hospital)
First DVT during 
pregnancy or 
puerperium
Cases: 74/313, 23.6% 
Controls: 23/353, 6.5% 
(figures for heterozygotes)
5.0 (3.1-8.3)
* Calculated from data given in article (StatsDirect).
# Study included in meta-analysis by Biron-Andreani et al. [69].
¤ Study included in meta-analysis by Robertson et al. [79].
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Table 2. FV Leiden and risk for venous thrombosis associated with pregnancy. Cohort studies.
 Study Country Self-reported 
study design
Study population Carriers of FVL Non-carriers of 
FVL






Family members of 
probands with documented 
DVT and FVL; ethnicity not 
reported
224 154 Documented DVT during 
pregnancy or puerperium
FVL carriers: 3 DVT in 
association with 157 
pregnancies










2,480 pregnant women; 









DVT during pregnancy or 
puerperium (history of VTE 
in 9)
3/270 FVL carriers had VTE





The Netherlands Retrospective 
follow-up 
(family) study
Family members of 
probands with documented 
DVT, positive family history 
for DVT, and FVL; ethnicity 
not reported
47 women with 
100 pregnancies
44 women with 
50 pregnancies
Documented DVT during 
pregnancy or puerperium 
(not all objectively 
diagnosed)
FVL carriers: 7 DVT in 
association with  100 
pregnancies
FVL non-carriers: 1 DVT in 












588 unselected primigravid 
women without history of 
thrombosis or hypertension 
// 
Women with history of DVT 
during pregnancy;
ethnicity not reported
16 572 Objectively diagnosed 
DVT during pregnancy or 
puerperium
0 DVT among primigravid 
cohort
//
4/33 (9.1%) of women with 
history of DVT were carriers 
of FVL vs. 13/540 (2.4%) 






















90% objectively diagnosed 
VTE (superficial thromboses 
included); during 
pregnancy or puerperium; 
previous VTE in 12
FVL homozygotes: 19 VTE (25 
SVT)
FVL non-carriers:












182 controls; 221 
pregnancies
Objectively diagnosed 
VTE during pregnancy or 
puerperium
FVL homozygotes: 3 women 
with DVT
FVL non-carriers:





Italy, one center Retrospective 
family cohort 
study
Parous family members of 
probands with documented 




81 First documented DVT in 
pregnancy or puerperium
FVL heterozygotes: 6 DVT 
in association with 242 
pregnancies
FVL non-carriers: 1 DVT 
in association with 215 
pregnancies
(FVL homozygotes: 1 DVT 











4,885 (1,602 White) 
pregnant women 
(exclusion: multiple 
pregnancy, history of VTE, 
anticoagulant therapy, 
known FVL status or 
antiphospholipid syndrome)
134 (White 97) 4,751 (White 
1,505)
First objectively diagnosed 
symptomatic DVT during 
pregnancy or puerperium
FVL carriers: 0 DVT in 
association with pregnancy
FVL non-carriers: 4 DVT in 
association with pregnancy 
(race not known)
-
* Calculated from data given in article (StatsDirect).
# Study included in meta-analysis by Biron-Andreani et al. [69].
¤ Study included in meta-analysis by Robertson et al. [79].
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Table 2. FV Leiden and risk for venous thrombosis associated with pregnancy. Cohort studies.
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previous VTE in 12
FVL homozygotes: 19 VTE (25 
SVT)
FVL non-carriers:












182 controls; 221 
pregnancies
Objectively diagnosed 
VTE during pregnancy or 
puerperium
FVL homozygotes: 3 women 
with DVT
FVL non-carriers:





Italy, one center Retrospective 
family cohort 
study
Parous family members of 
probands with documented 




81 First documented DVT in 
pregnancy or puerperium
FVL heterozygotes: 6 DVT 
in association with 242 
pregnancies
FVL non-carriers: 1 DVT 
in association with 215 
pregnancies
(FVL homozygotes: 1 DVT 











4,885 (1,602 White) 
pregnant women 
(exclusion: multiple 
pregnancy, history of VTE, 
anticoagulant therapy, 
known FVL status or 
antiphospholipid syndrome)
134 (White 97) 4,751 (White 
1,505)
First objectively diagnosed 
symptomatic DVT during 
pregnancy or puerperium
FVL carriers: 0 DVT in 
association with pregnancy
FVL non-carriers: 4 DVT in 
association with pregnancy 
(race not known)
-
* Calculated from data given in article (StatsDirect).
# Study included in meta-analysis by Biron-Andreani et al. [69].
¤ Study included in meta-analysis by Robertson et al. [79].
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5.7 Pre-eclampsia
Pre-eclampsia is an important cause of maternal and fetal morbidity complicating 
2-7% of pregnancies [87]. Pre-eclampsia is one of the leading causes of maternal 
mortality [64,65]. In Finland, pre-eclampsia and eclampsia cause about 12% of 
maternal deaths [67].
Pre-eclampsia is defined as high blood pressure after 20 weeks of gestation 
in a previously normotensive woman plus new-onset proteinuria. Definitions 
vary slightly among studies, but usually the ACOG criteria [88] are applied. 
Pre-eclampsia may be mild, just fulfilling the definition, or severe, including 
symptoms and findings like thrombocytopenia, elevated liver enzymes, epigastric 
or right upper-quadrant pain with nausea or vomiting, oliguria, cerebral 
symptoms, pulmonary edema, and seizures [87]. Pre-eclampsia is ultimately 
cured only by delivery, therefore often leading to preterm birth. Prematurity and 
fetal growth restriction, which is often associated with pre-eclampsia, affect the 
health of the newborn [87].
The etiology of this heterogeneous disease entity is still unknown [87,89]. Pre-
eclampsia can be divided to placental pre-eclampsia originating from abnormal 
placental perfusion, and maternal pre-eclampsia originating from pre-existing 
problems in mother [90]. However, in an individual, pre-eclampsia may be 
caused by variable interaction of placental/fetal and maternal factors [89]. 
Factors that have been associated with an increased risk for pre-eclampsia 
include primigravidity, multifetal gestation, previous pre-eclampsia, obesity, 
pregestational diabetes, chronic hypertension or renal disease, family history of 
pre-eclampsia, and controversially thrombophilia [87]. Endothelial dysfunction is 
considered to be an important factor in its development [90,91]. Endothelial cell 
injury can lead to the activation of coagulation, vasoconstriction, reduced plasma 
volume due to “leaking endothelium”, and glomerular capillary protein leak [91]. 
A thrombotic tendency may exacerbate the activation of coagulation.
5.7.1 FV Leiden and pre-eclampsia
Numerous studies with different designs have assessed association between pre-
eclampsia and FV Leiden and many meta-analyses have tried to determine the 
true association.
In a meta-analysis by Dudding and Attia [92], the OR for association of FV Leiden 
with pre-eclampsia varied from 0.2-12.9 in 24 case-control studies. Studies 
were so heterogeneous that pooled OR was not calculated. In seven studies 
specifying severe pre-eclampsia, pooled OR was 3.0 (95% CI 2.0-4.7). These 
studies included 753 cases and 1,120 controls of women with reported ethnicity 
of Caucasian or Israeli. Heterozygous and homozygous carriers of FV Leiden were 
pooled.
In a meta-analysis by Lin and August [93], the combined OR for FV Leiden in 
12 case-control studies assessing all pre-eclampsia was 1.8 (95% CI 1.1-
2.9). Heterozygous and homozygous carriers were pooled. Statistical test for 
heterogeneity was significant (p=0.04) and a funnel plot analysis suggested 
publication bias (small negative studies missing). The studies included 
1,798 cases and 1,471 controls of mostly Caucasian origin; in one study 
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the participants were Japanese and in one Australian study only 83% were 
Caucasian. In their meta-analysis of 11 case-control studies assessing severe 
pre-eclampsia, the pooled OR for FV Leiden was 2.2 (95% CI 1.3-3.9). Statistical 
test for heterogeneity was significant (p=0.009), but there were no suggestion of 
publication bias. These studies included 1,135 cases and 1,471 controls of mostly 
Caucasian origin; in three studies, 90-95% of women were Caucasian and in one 
study only 40% were Caucasian. As FV Leiden is mostly limited to the Caucasian 
population, inclusion of other ethnicities may influence the results. 
In a systematic review and meta-analysis by Robertson et al. [79], heterozygous 
and homozygous carriers of FV Leiden were analyzed separately for the risk of 
pre-eclampsia. Fourteen studies assessing heterozygous FV Leiden had pooled 
OR of 2.2 (95% CI 1.5-3.3) with signs of heterogeneity (p=0.04). The studies 
included both mild and severe pre-eclampsia and study designs varied from 
retrospective case-control and cohort studies to one prospective cohort study. 
Studies included 1,951 cases and 1,971 controls, ethnicity was not specified. 
When five studies of severe pre-eclampsia were analyzed separately, the pooled 
OR for heterozygous FV Leiden was 2.0 (95% CI 1.2-3.4) without signs of 
heterogeneity. Five studies assessing homozygous FV Leiden had pooled OR of 
1.9 (95% CI 0.4-7.9) without signs of heterogeneity. These studies included 612 
cases and 536 controls, ethnicity was not specified.
In a recent systematic review and meta-analysis of nine prospective cohort 
studies assessing the association between FV Leiden and pre-eclampsia by Rodger 
et al. [3], the pooled OR was 1.23 (95% CI 0.89-1.70) indicating that FV Leiden 
is not associated with an increased risk for pre-eclampsia. There were no signs 
of heterogeneity. The meta-analysis comprised 21,833 unselected prospectively 
enrolled women with a spontaneous singleton pregnancy from Ireland, Israel, 
the United States, the United Kingdom, Australia, Greece, Sweden, and Canada. 
FV Leiden carriers had a 3.8% absolute risk for pre-eclampsia whereas in FV 
Leiden non-carriers the absolute risk was 3.2%. The prevalence of FV Leiden in 
these populations varied from 2.7% to 10.9%, ethnicity of participants was not 
specified.
Only two population-based studies of at least predominantly Caucasian study 
populations assess FV Leiden as a risk factor for pre-eclampsia. Both are 
retrospective registry-based cohort studies of geographically well-defined 
area, one from Scotland [94] (included in meta-analyses by Dudding, Lin, and 
Robertson [79,92,93]), and one from Norway [95] (included in meta-analysis 
by Dudding [96]). Both studies pooled heterozygotes and homozygotes in their 
analyses. The study from Scotland analyzed 494 pre-eclampsia cases and 163 
controls, ethnicity was not reported. In this study, FV Leiden was not associated 
with an increased risk for pre-eclampsia (OR 0.9, 95% CI 0.4-2.1) [94]. The 
study from Norway analyzed 14,393 pregnancies of 5,874 women, ethnicity was 
not reported. In this study, FV Leiden was associated with an increased risk for 
pre-eclampsia (OR 1.6, 95% CI 1.2-2.3). As the study analyzed pregnancies, not 
women, several pregnancies for each women were included [95]. 
In a study by Dudding et al. [96], FV Leiden was not significantly associated with 
an increased risk for verified pre-eclampsia in a cohort of pregnant women (FV 
Leiden in 17/243 cases and 204/4,206 controls, OR 1.19, 95% CI 0.64-2.23). 
However, when they combined their study with five other cohort studies in meta-
analysis to increase power, association between FV Leiden and pre-eclampsia 
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became significant (pooled OR 1.49, 95% CI 1.13-1.96). The pooled analysis 
included 860 cases and 18,340 controls from the United Kingdom, Sweden, the 
United States (two studies), Norway, and Ireland.
Meta-analyses described above include partly the same studies. A recent 
Canadian study by Kahn et al. [97] has not been included in any of them. 
This nested case-control study within a prospective cohort of pregnant women 
consisted of 113 pre-eclampsia cases and 443 controls. The study included 
different ethnicities, which were not specified. FV Leiden was not associated with 
an increased risk for pre-eclampsia (OR 1.1, 95% CI 0.4-2.7). The study showed 
that histopathologic features consistent with placental underperfusion were more 
common in cases than in controls. However, FV Leiden was not associated with 
these features. 
Taken together, individual studies and meta-analyses assessing the association 
between FV Leiden and pre-eclampsia have yielded very conflicting results. The 
association, if any, seems to be modest.
5.8 Stillbirth
Although stillbirth is a rare pregnancy complication in developed countries, it 
causes strong emotional burden for the particular family. The stillbirth rate has 
been estimated to be 4.2-6.8 per 1,000 deliveries in developed countries [98]. In 
Finland, like in other Nordic countries, the stillbirth rate is even less and among 
the smallest in the world [99]. However, due to different definitions the stillbirth 
rate is difficult to compare between countries.
The precise definition of stillbirth varies in different countries and in different 
studies. The definition is based on gestational age of the fetus at the time of 
stillbirth (usually ≥20-24 weeks) or on the fetal weight (usually ≥500g) [99-
101]. In Finland, stillbirth is defined as stillbirth at or after 22 weeks of gestation, 
or fetal weight ≥ 500 g [99]. Stillbirths are subclassified as early stillbirths at 
or before 28 weeks of gestation and late stillbirths after 28 weeks of gestation 
[101].
Risk factors for stillbirth include multiple pregnancy, nulliparity, advanced 
maternal age, pre-pregnant obesity, smoking, maternal diseases, previous 
stillbirth, and low socio-economic status [101,102]. The causes of stillbirth include 
maternal infections, placental lesions like abruptio placentae, or major infarction 
of the placenta, umbilical cord complications like prolapse, strangulation, or 
knot, and congenital anomalies [101,102]. However, 25-60% of stillbirths remain 
unexplained [101,102]. Thrombophilia has been hypothesized as one possible 
risk factor for stillbirth [100-102].
5.8.1 FV Leiden and stillbirth
Studies assessing the association between FV Leiden and stillbirths vary in many 
respects. Study designs, selection of cases and controls, definition of stillbirth, 
reporting of ethnicity, inclusion of women with previous thromboembolism, and 
inclusion of homozygotes in analyses differ. Case-control and cohort studies are 
summarized in tables 3 and 4.
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In case-control studies (table 3), the odds ratio for association between FV Leiden 
and stillbirth varied from 0.7 to 9.2. In six of the nine studies, the association 
was statistically significant. Only two of the studies assessing unexplained 
stillbirth reported the study population to be Caucasian [103,104].
In retrospective cohort studies (table 4), the odds ratio varied from 1.3 to 4.4. 
In only one of these studies, the association was statistically significant (OR 2.2, 
95% CI 1.5-3.4), but there the studied unit was not a woman but pregnancy 
[95]. In the only prospective cohort study to this date [105] (table 4), FV Leiden 
was associated with almost a 9-fold risk for stillbirth (OR 8.85, 95% CI 1.6-48.9). 
Cohort consisted of 1,707 nulliparous healthy women with a singleton pregnancy 
and heterogeneous ethnic background. However, there were only six stillbirths in 
the cohort.
In a meta-analysis by Rey et al. in 2003 [106], the pooled OR for association 
between FV Leiden and fetal loss after 19 weeks of gestation was 3.3 (95% 
CI 1.8-5.8). Analysis included six retrospective studies with no signs of 
heterogeneity (372 cases, 1,888 controls). In a meta-analysis by Dudding 
et al. in 2004 [92], the pooled OR for FV Leiden was 2.8 (95% CI 1.3-6.2) 
when assessing only isolated third trimester fetal losses. There were no signs 
of heterogeneity in this post hoc subanalysis of five studies. In a systematic 
review and meta-analysis by Robertson et al. in 2006 [79], the pooled OR for 
association between heterozygous FV Leiden and late fetal loss (third trimester) 
was 2.06 (95% CI 1.1-3.9) with no signs of heterogeneity. Analysis included six 
retrospective case-control and cohort studies with 151 cases and 1,503 controls, 
ethnicities were not reported. In a recent review by Werner et al. [100], a meta-
analysis of eleven heterogeneous studies yielded a pooled OR of 3.6 (95% CI 
2.1-6.2). The above four meta-analyses included partly same studies.
Taken together, the results of individual studies are partly conflicting, perhaps 
resulting from heterogeneity of the studies. In meta-analyses, FV Leiden has 
been associated with quite a constant 2-fold to 3-fold increased risk. Population-
based studies are few.
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Table 3. FV Leiden and risk for stillbirth. Case-control studies.
 Study Country Self-reported 
study design




Prevalence of FVL OR (95% CI)
Gris et al. 
1999 [107]
France Case-control Women without history 
of thromboembolism, 
miscarriage, PIH, or infection 
during pregnancy; ethnicity 
not reported
232 464 (matched for age 
and parity)







Israel Case-control Jewish Ashkenazi, non-
Ashkenazi, or mixed Ashkenazi
12 110 parous women 
without thromboembolic 
complications; matched 
for age and family origin
>23 Yes Cases: 3/12, 25%
Controls: 7/110, 6% 
(homozygotes included)
4.9 (1.1-22)
Martinelli et al. 
2000 [103]
Italy Case-control White women ≤35 years 
without history of venous 
thrombosis
67 232 ≥20 gestational 
weeks
Yes Cases: 5/67, 7%
Controls: 6/232, 3% 
(all heterozygous)
3.2 (1.0-10.9)
Many et al. 
2002 [109]
Israel Case-control Ashkenazi and non-Ashkenazi 40 80 healthy parous 




Yes Cases: 3/40, 7.5%
Controls: 3/80, 3.8% 
(all heterozygous)
1.5 (0.7-3.6)
Weiner et al. 
2004 [110]





Yes Cases: 9/53, 17%
Controls: 5/59, 8.5% 
(homozygotes included)
2.2 (0.6-9.0)*
Gonen et al. 
2005 [111]
Israel Case-control Different  ethnic groups in 
Israel (cases and controls 
matched for ethnicity)
37 46 parous women 
without history of 
stillbirth, recurrent 




Yes Cases : 4/37, 10.8%
Controls: 7/46, 15.2% 
(homozygotes included)
0.68 (0.1-3.0)
Sottilotta et al. 
2006 [104]













Kocher et al. 
2007 [112]
USA Case-control White (from a cohort of 4872 





96 (matched for age 
and gravidity)
Birth weight of 
fetus ≥500g
No Cases: 6/32, 19%
Controls: 2/96, 2%
10.9 (2.1-57)






Ethnicity not reported 67 women (33 with 
“placental stillbirth”; 
48% nulliparous)
637 low-risk nulliparous 
pregnant women from 




No Cases: 16/67, 23.9%
Controls: 24/637, 3.8%
8.0 (4.0-16.0)
* Calculated from the data given in the article (StatsDirect).
Abbreviations: PIH, pregnancy induced hypertonia
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Table 4. FV Leiden and risk for stillbirth. Cohort studies.










Stillbirth OR (95% CI)












Parous women of EPCOT 
study; ethnicity not 
reported
141 395 >28 gestational 
weeks
No FVL carriers: 5/410, 1.2% 
pregnancies















propositi and relatives 




121 >20 gestational 
weeks
No FVL carriers: 13/228, 5.7%
FVL non-carriers: 6/121, 
5.0%
1.3 (0.5-3.7)





Parous  family members 








Yes FVL carriers: 7/65, 10.8%
FVL non-carriers: 1/44, 
2.3%
4.4 (0.5-35.6)


















No FVL carriers: 7/64, 11%
Controls: 2/52, 4%
2.0 (0.4-9.7)










No FVL carriers: 1 
intrauterine death

























5,874 women with 14,474 















FVL Carriers: 26/1,049, 
2.5% of pregnancies
FVL non-carriers: 










1,707 healthy nulliparous 
women enrolled <22 
gestational weeks; 
singleton pregnancies; no 





1,614 ≥20 gestational 
weeks or birth 
weight of fetus 
≥400g
Yes FVL carriers: 2/93, 2.2%
FVL non-carriers: 4/1,633, 
0.2% #
8.85 (1.6-48.9)
* Calculated from the data given in the article (StatsDirect).
# Numbers from meta-analysis by Rodger et al. [3].
Abbreviations: EPCOT, European Prospective Cohort on Thrombophilia
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5.9 Preterm birth
Preterm birth (birth before 37 completed weeks of gestation), occurring in 5-13% 
of deliveries in developed countries, is a major cause of neonatal morbidity and 
mortality [119,120]. In Finland, preterm delivery occurs in about 5% of deliveries 
[99].
Preterm birth is a heterogeneous clinical entity. Many pregnancy complications 
may lead to it, but in about half of the cases the cause of preterm birth remains 
unknown [120]. Preterm birth can be categorized to 1) spontaneous preterm 
birth due to a) onset of preterm labour or b) preterm premature rupture of 
membranes (PPROM), and to 2) indicated preterm birth including a) induced 
labour and b) cesarean section performed for maternal or fetal reasons [121]. 
Preterm birth can also be categorized by gestational age to extremely preterm 
(<28 gestational weeks), severely preterm (28-31 gestational weeks), and 
late preterm birth (32-36 gestational weeks) [121]. Preterm births at 32-36 
gestational weeks have also been sub-classified to moderate prematurity (32-33 
gestational weeks), and to near term (34-36 gestational weeks) [119]. However, 
as infants born at 34-36 gestational weeks are immature and have a greater risk 
of morbidity and mortality than infants born at term, it is recommended to refer 
them as late-preterm infants [122]. As a result, late preterm birth has different 
definitions in the literature. The etiological causes of preterm birth are partly 
different during different phases of pregnancy [119]. 
Inflammatory mechanisms have a key role in the initiation of normal labour [5]. 
Mechanisms that are thought to be involved in the initiation of preterm labour 
include infection or inflammation, uteroplacental ischemia or hemorrhage, uterine 
overdistention, stress, and other immunologically mediated processes [119]. In 
addition, genetic factors and race contribute to preterm birth [119,120]. Factors 
that are associated with an increased risk for preterm birth include multiple 
gestation, uterine anomalies, maternal diseases, extremes of maternal age, low 
pre-pregnancy BMI, smoking, and low socioeconomic and educational status 
[119,120].
Theoretically, thrombophilia could influence the initiation of preterm labour via 
thrombosis in the placenta causing uteroplacental ischemia or oxidative stress, 
or by activating inflammatory mechanisms. Polymorphisms in genes involved 
in coagulation and inflammation, including factor V, have been associated with 
preterm birth [123,124].
5.9.1 FV Leiden and preterm birth
Only three heterogeneous reports have shown positive association between FV 
Leiden and preterm birth. One study compared 205 very low birth weight (VLBW) 
preterm infants with 205 term infants (OR for FV Leiden 2.1, 95% CI 1.01-4.4) 
[125]. One study observed increased prevalence of FV Leiden in 50 women with 
preterm birth compared with the population prevalence (18% vs. 6.3%) [126]. 
FV Leiden has also been associated with preterm birth with evidence of placental 
hemorrhage (OR 4.8, 95% CI 1.6-14.2) [127]. Other current studies have not 
found a significant association between FV Leiden and preterm birth [112,128-
132]. Many of the studies are small or have other limitations. Study design, 
selection of cases and controls, ethnicity, exclusion criteria, and even definition of 
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preterm birth differ. Case-control and cohort studies are summarized in tables 5 
and 6. At present, no prospective unselected cohort studies have been published.
Taken together, only a limited number of heterogeneous studies have assessed 
the association between FV Leiden and preterm birth, and with conflicting results.
Cervical insufficiency is one cause of preterm birth. In one study, FV Leiden 
was associated with a 4-fold risk for cervical insufficiency and subsequent 
preterm birth (OR 4.2, 95% CI 1.5-13.6) [133]. The authors speculated that 
increased thrombin production caused by FV Leiden could intensify activation of 
inflammatory processes in the cervix leading to cervical insufficiency.
5.10 Current recommendations for screening of inherited 
thrombophilia in association with pregnancy complications
Screening for thrombophilia has been under debate since the first findings 
of association between thrombophilia and placenta-mediated pregnancy 
complications. However, screening for a risk factor is indicated only if the 
result influences the treatment of the patient [7]. LMWH is increasingly used 
in women at increased risk for these complications [134]. However, with the 
current knowledge, prophylaxis with low molecular weight heparin (LMWH) is 
not routinely recommended in women with a prior placenta-mediated pregnancy 
complication (pregnancy loss, pre-eclampsia, IUGR, placental abruption), 
whether they have inherited thrombophilia or are unselected [3,7,134]. Further 
randomized controlled trials are urgently needed.
In the light of this, in current guidelines, screening for inherited thrombophilia, 
or FV Leiden, is not recommended in unselected women with placenta-mediated 
pregnancy complications [7,134]. However, screening for thrombophilia in women 
with personal or family history of venous thrombosis is considered reasonable as 
it may influence the timing and intensity of venous thrombosis prophylaxis during 
pregnancy and puerperium [7,134]
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Table 5. Leiden and risk for preterm birth. Case-control studies.




Cases Controls Preterm birth 
definition
Exclusion criteria Prevalence of FVL OR (95% CI)
Göpel et al. 
1999 [125]
Germany Case-control White infants 205 preterm 
infants with very 
low birth weight
205 random healthy 
term singletons
<37 gestational 





(carrier status not specified)
2.1 (1.01-4.4)
Erhardt et al. 
2000 [126]










Valdez et al. 
2004 [128]




1) healthy adults, 
male/female ratio 1:1
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54 mothers with 
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Chronic illness, infection, 
drug abuse, bicornate uterus, 
incompetent cervix, multiple 
gestation, erythroblastosis, 











Mainly White 397 mothers of 
preterm very 
low birth weight 
singletons
278 mothers of term 
singletons
<37 gestational 
weeks and birth 
weight <1500 g 
(VLBW)




Kocher et al. 
2007 [112]
USA Case-control White 99 women 294 women matched 




cervix, thalassemia, vWD, 




(carrier status not 
specified)
0.99 (0.4-2.3)
Uvuz et al. 
2009 [131]
Turkey Case-control Ethnicity not 
reported
50 women 50 healthy women 
with uncomplicated 




PROM, chronic hypertension, 
diabetes mellitus, liver or renal 
disease, fetal anomaly, multiple 


















206 women 444 women with 
term delivery
(for each case two 
next delivering 






Multiple pregnancy, age <18, 
severe chronic illness (other 
than asthma, hypertension 
or diabetes), placenta previa, 
history of incompetent cervix, 





* Calculated from the data given in the article (StatsDirect).
Table 6. FV Leiden and risk for preterm birth. Cohort studies.
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6 AIMS OF THE STUDY
The main aim of the study was to assess FV Leiden as a risk factor for pregnancy 
complications in which prothrombotic mechanisms may play a part. The specific 
aims were:
I
To assess the magnitude of the risk for venous thromboembolism during 
pregnancy and puerperium caused by FV Leiden. To assess the interaction 
between FV Leiden and other known risk factors for venous thrombosis. To 
estimate the absolute and attributable risks of FV Leiden on individual and 
population levels.
II
To assess FV Leiden as a risk factor for pre-eclampsia and eclampsia. To assess 
FV Leiden as a risk factor in subgroups of pre-eclampsia: severe pre-eclampsia, 
early pre-eclampsia, and pre-eclampsia with IUGR.
III
To assess FV Leiden as a risk factor for unexplained stillbirth. To assess early and 
late unexplained stillbirth separately.
IV
To assess FV Leiden as risk a factor for preterm birth. To assess FV Leiden as a 
risk factor in clinical subgroups of preterm birth: early and late preterm birth, 
and preterm birth without other pregnancy complications.
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7 MATERIALS AND METHODS
7.1 Study design
The study design is a nested case-control study within a fixed cohort of 
100,000 consecutive pregnant women in Finland. Study population is ethnically 
homogeneous and represents Finnish women from all over the country with 
pregnancies lasting beyond 8 to 12 weeks of gestation.
A nested case-control strategy is feasible when resources are scarce. It yields 
readily generalizable results and offers advantages over case-control designs, 
nested in an unknown cohort, to assess and ensure internal validity of the results. 
Also, it allows calculation of the same parameters as in true cohort studies.
In this study, selection bias was avoided by using the Hospital Discharge Register 
in identification of cases and controls. Accuracy of registry-based diagnoses was 
ensured by checking medical records of all participants. Strict diagnostic criteria 
were used for each studied disease entity. Information bias was minimized by 
collecting data from medical records and questionnaires on to standardized forms 
blinded for laboratory results.
7.2 Ethical considerations
The study was approved by the ethics committee of the Finnish Red Cross Blood 
Service (February 18th, 1997) and by the Ministry of Social Affairs and Health 
(July 16th, 1997, Dnro18/08/97). The Population Register Centre gave permission 
for address data on February 15th, 2000 (1273/40/99). All participants gave 
written informed consent. Every hospital gave permission to use medical record 
archives. The study was planned and conducted according to the Personal Data 




At the beginning of the study in 1997, Finland had a population of 5.15 million 
people with about 58,000 births per year. The Finnish population is ethnically 
very homogenous Caucasian. According to Statistics Finland (March 19th, 2010), 
in 1997 only 118,070 persons living in Finland were born outside Finland, and of 
these, only 34,476 were born outside Europe. Of these, 9,957 were women aged 
15 to 49 years, i.e., 0.8% of the same-aged women in the population. Women 
were considered for the study if they had Finnish unique identification code, and 
if their mother tongue was Finnish or Swedish, which practically excludes all first 
generation migrants. Mother tongue was ascertained from the Population Register 
Centre from where also the addresses of the participants were obtained. In the 
European Union, processing of personal data revealing racial or ethnic origin is 
prohibited (Directive 95/46/EC of the European Parliament and of the Council of 
24 October 1995 on the protection of individuals with regard to the processing of 
personal data and on the free movement of such data).
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7.3.2 National Register of Blood Group and Blood Group Antibodies of 
Pregnant Women
In Finland, practically all pregnant women contact their local Maternity Welfare 
Clinic during 8th to 12th weeks of pregnancy. Attending antenatal care is a 
prerequisite for the benefits given by the Social Insurance Institution. At the first 
visit, samples are taken for blood group serology tests, which are performed in 
the Finnish Red Cross Blood Service at the department of antenatal serology. 
The department maintains the National Register of Blood Groups and Blood 
Group Antibodies of Pregnant Women from which data for 100,000 consecutive 
pregnant women were obtained. Only the first pregnancy of each woman after 
January 1st, 1997 (index pregnancy) was included in the cohort. The time scale 
of identification of 100,000 consecutive pregnant women was from January 1997 
to October 1998.
7.3.3 National Hospital Discharge Register
The National Institute for Health and Welfare maintains the National Hospital 
Discharge Register with diagnoses classified according to the International 
Classification of Diseases (ICD-10 since 1996). Up to three diagnoses are 
registered for each inpatient care period. Personal unique identification 
codes were used to link the two registers to obtain diagnoses for the 100,000 
consecutive pregnant women. ICD-10 codes retrieved from the Hospital Discharge 
register are shown in the appendix. As the pregnancies of women identified last 
ended in 1999, diagnoses from the Hospital Discharge Register were obtained 
from the years 1997-1999. When identification of pregnant women started, the 
new ICD-codes had been in use for one year.
7.3.4 Recruitment of cases and controls
Figure 3 outlines the recruitment of cases and controls. In the cohort of 100,000 
pregnant women, 503 women had an incorrect unique identification code and 
were excluded. Of the rest, 5,562 women had some pregnancy complication in 
the Hospital Discharge Register and 93,935 had none of these.
When planning the study, the aim was to get 500 cases with pre-eclampsia and 
preterm birth, and four controls per case. Because the participation rate was 
assumed to be about 75%, somewhat more case-candidates were invited to the 
study. All possible cases of pregnancy-associated venous thrombosis and stillbirth 
were invited. All eligible controls were planned to be used in all four sub-studies.
After identifying case-candidates and control-candidates, their addresses and 
mother tongue were obtained from the Population Register Centre. An invitation 
letter was sent to women who fulfilled the invitation criteria (alive, mother 
tongue Finnish or Swedish, residence in Finland). Women were informed about 
the study and they were asked to return a form with information whether they 
wanted to participate in the study or not. Those who did not respond were sent a 
reminder. Altogether 4,548 invitations and 1,832 reminders were sent, and 2,269 
women participated (49.9%). Questionnaires and tubes for blood samples along 
with a form for informed consent were sent to those who wanted to participate. 
Participants gave blood samples for serological and DNA tests in a laboratory 
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Figure 3. Outline of recruitment 
of cases and controls.
of their choice or in the nearest regional blood centre. Blood samples, filled 
questionnaires, and informed consents were mailed to the Helsinki Blood Centre.
The medical records of participants were reviewed in 49 maternity hospitals in 
Finland to gather clinical data. All data were collected on standardized forms 
blinded to laboratory results.
7.4 Cases and controls
7.4.1 Study I – Pregnancy-associated venous thrombosis
Of the 100,000 consecutive pregnant women, 95 had an ICD-code for any venous 
thrombosis. Of those, 88 fulfilled the invitation criteria and 70 (80%) participated. 
In 34 women (cases) an objectively diagnosed deep venous thrombosis (DVT) 
was verified from medical records: 21 had distal DVT, 11 had proximal DVT, 1 
had pulmonary embolism, and 1 had cerebral vein thrombosis. Of the 36 women 
excluded from the study, 12 had superficial venous thrombosis, 4 had non-
objectively diagnosed thrombosis, and 20 had had venous thrombosis before or 
more than 10 weeks after the index the pregnancy.
Controls were sampled randomly (every 46th pregnant woman) from the 93,935 
women without pregnancy complications in the Hospital Discharge Register. Of the 
2,043 women, 1,930 fulfilled the invitation criteria and 843 (44%) participated. 
After review of medical records, 641 women were eligible as controls (no venous 
or arterial thrombosis, pre-eclampsia, or stillbirth in the index pregnancy or 
before, and no thrombosis prophylaxis, miscarriage, premature birth, or IUGR in 
the index pregnancy).
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7.4.2 Study II – Pre-eclampsia
Of the 100,000 consecutive pregnant women, 1,084 had an ICD-10 code for pre-
eclampsia (O14.0, O14.1, O14.9) or eclampsia (O15.0, O15.1, O15.2, O15.9). 
The first 685 consecutive women were picked as case candidates. Of them, 
665 fulfilled the invitation criteria and 411 participated (62%). A review of their 
medical records revealed that 248 women (60%) fulfilled the strict diagnostic 
criteria for pre-eclampsia (cases). 
The control group comprised two randomly selected subgroups. First, every 
46th from the 93,935 women without pregnancy complications was selected as 
a control candidate. Of the 2,043 women, 1,930 fulfilled the invitation criteria 
and 843 participated (44%). After a review of medical records, 641 women were 
eligible as controls (no pregnancy complications in the index pregnancy and no 
history of hypertension, stillbirth, pre-eclampsia, or thrombosis). Second, from 
the 4,478 women with a pregnancy complication other than pre-eclampsia 
(stillbirth, miscarriage, premature birth, IUGR, or venous or arterial thrombosis), 
1,965 women were picked as control candidates. Of them, 1,838 fulfilled the 
invitation criteria and 1,022 women participated (56%). Of them, every 24th was 
selected as a control to ascertain that the proportion of women with complications 
other than pre-eclampsia would be the same as in the population. A review of 
their medical records verified that 38 were eligible (no pre-eclampsia). Altogether, 
the control group comprised 679 women. See flow-chart in the Study II (Fig. 1).
7.4.3 Study III – Stillbirth
Of the 100,000 consecutive pregnant women, 224 had an ICD-10 code for 
stillbirth (O36.4). Of them, 222 fulfilled the invitation criteria and 120 participated 
(54%). A review of their medical records revealed that 44 women fulfilled the 
criteria for unexplained stillbirth (cases). Of the excluded women, 22 had 
intrauterine fetal deaths before gestational week 22. In two women the diagnosis 
was wrong and in two women relevant information was missing. Furthermore, 16 
stillbirths due to lethal congenital developmental conditions, 23 stillbirths due to 
umbilical cord complications, and 14 stillbirths due to infections were excluded 
(three women had infection and umbilical cord complication). There were no birth 
injuries, isoimmunizations, or advanced stage twin-twin transfusion syndromes.
The control group comprised two randomly selected subgroups. First, every 
46th woman of the 93,935 women without pregnancy complications was 
selected as a control candidate. Of the 2,043 control candidates, 1,930 fulfilled 
the invitation criteria and 843 participated (44%). After a review of medical 
records, 729 women were eligible as controls (no pregnancy complications in 
the index pregnancy or previous stillbirth). Second, of the 5,338 women with 
a pregnancy complication other than stillbirth, 2,426 were chosen as control 
candidates. Of them, 2,294 fulfilled the invitation criteria and 1,313 participated 
(57%). Of them, every 28th was randomly picked as a control to ascertain that 
the proportion of women with complications other than stillbirth would be the 
same as in the population. A review of their medical records verified that 47 were 
eligible (no history of stillbirth). Altogether, the control group comprised 776 
controls. See flow-chart in the Study III (Fig. 1).
43
7 MATERIALS AND METHODS
7.4.4 Study IV – Preterm birth
Of the 100,000 consecutive pregnant women, 1,402 had an ICD-code for 
preterm birth (ICD O60). The first 670 consecutive women were picked up as 
case-candidates. Of them, 623 fulfilled the invitation criteria and 331 participated 
(53%). A review of their medical records revealed that 324 women fulfilled the 
criteria for preterm birth (cases).
Control candidates were randomly sampled from the cohort of 100,000 women. 
First, every 46th woman of the 93,935 women without pregnancy complications 
(preterm birth, birth of a small-for-gestational-age fetus, pre-eclampsia, 
miscarriage, stillbirth, or arterial or venous thrombosis) in the index pregnancy 
was selected as a control candidate (2,043). Of them, 1,930 fulfilled the invitation 
criteria and 843 (44%) participated. A check of their medical records verified that 
705 were eligible as controls (no pregnancy complications in the index pregnancy 
and no previous preterm birth). Second, the control group was supplemented 
to avoid selection bias. Of the 4,160 women with complications in the index 
pregnancy, 1,959 consecutive were picked as control candidates. Of them, 1,874 
fulfilled the invitation criteria and 1,093 (58%) participated. Of those, every 23rd 
was randomly picked as a control (47). Supplementation ascertained that the 
proportion of pregnancy complications other than preterm birth, some possibly 
associated with FV Leiden, was the same in controls as in the cohort of 100,000 
women. Altogether the control group comprised 752 women. See flow-chart in 
the Study IV (Fig. 1).
7.4.5 Population sample
A population sample of 644 first-time blood donors was genotyped to estimate 
the prevalence of the seven polymorphisms in the Finnish population.
7.5 Definitions
Venous thrombosis was defined as objectively diagnosed distal or proximal deep 
venous thrombosis (DVT), pulmonary embolism, or cerebral vein thrombosis 
during the index pregnancy or 10 weeks after delivery or termination of 
pregnancy. The verification of thrombosis was done by ultrasound, venography, 
magnetic resonance imaging, or computed tomography. Superficial venous 
thromboses were excluded. First-time and recurrent venous thromboses were 
considered as a manifestation of the same thrombotic disease. Cases with 
recurrent thrombosis were included but cases with first-time venous thrombosis 
were also analyzed separately.
Pre-eclampsia was defined as the systolic blood pressure ≥140 mmHg and the 
diastolic blood pressure ≥90 mmHg with new-onset proteinuria (repeatedly 
≥0.3 g/l or ≥0.5 g/24 hours or dipstick ≥+ representing values ≥0.3 g/l) after 
20 weeks of pregnancy in a previously normotensive woman. Eclampsia was 
defined as seizure associated with pre-eclampsia. Severe pre-eclampsia was 
defined as the systolic blood pressure >160 mmHg measured at least twice, the 
diastolic blood pressure >110 mmHg measured at least twice, proteinuria >3 g/
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l, or proteinuria >5 g/24 hours. Eclampsia and pre-eclampsia complicated with 
severe physical symptoms (epigastric pain, visual symptoms, oliguria, dyspnea) 
were also classified as severe pre-eclampsia. Early pre-eclampsia was defined as 
the onset of pre-eclampsia before the gestational week 34. (Definitions slightly 
modified from the ACOG criteria [88].)
Unexplained stillbirth was defined as intrauterine fetal death at 22 weeks of 
gestation or later (according to the definition used in Finland [99]) excluding 
stillbirths due to lethal congenital developmental conditions (chromosome 
anomalies, malformations), umbilical cord complications (e.g. prolapse, true knot, 
strangulation), infections (e.g. chorionamnionitis, cytomegalovirus, parvovirus, 
Listeria monocytogenes),  birth injuries, isoimmunizations, and advanced stage 
twin-twin transfusion syndromes. Placental infarction and placental abruption 
were not excluded as they could be etiologically related to the exposure and 
outcome. Late stillbirth was defined as intrauterine fetal death at 28 weeks of 
gestation or later.
Preterm birth was defined as birth at or after 22 and before 37 completed weeks 
of gestation (according to the definition used in Finland [99]). Preterm birth was 
defined early when it occurred before 32 weeks, and late when it occurred at or 
after 32 weeks of gestation. Although the exact determination of gestational age 
is difficult, the best clinical estimate from the medical records was used in this 
study.
Intrauterine growth restriction (IUGR) was defined as the child’s birth weight 
being minus two standard deviations or less for gestational age. Birth weight 
standards based on the Finnish population, separate for girls and boys, were 
available from the gestational day 195 onwards [135]. 
Maternal age was the age at the first visit at to the antenatal care.
Body mass index (BMI) was defined as pre-pregnancy weight in kilograms divided 
by the square of height in meters (kg/m2). Pre-pregnancy weight and height 
were collected from medical records and confirmed from questionnaires.
7.6 Laboratory methods
Genomic DNA was isolated from blood samples collected in EDTA tubes by using 
a commercial kit (QIAamp® DNA Blood Mini Kit, Qiagen, Hilden, Germany). 
Subjects were genotyped for seven polymorphisms in the Finnish Genome Center. 
Genotyping method was based on restriction enzyme digestions after PCR. 
Assays were performed multiplexed in a total volume of 5 μl in the conditions 
described elsewhere [136,137]. A fluorescent label (6-FAM, NED, or HEX) 
was included in the primer. An additional restriction site served as an internal 
control for the digestion reaction. If a natural digestion site was lacking, primer-
induced restriction analysis was used. PCR products were digested with 1U of 
specific restriction enzyme (New England Biolabs, Beverly, MA, USA) and then 
separated with the ABI PRISM 377 (PE Applied Biosystems, Foster City, CA, USA) 
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DNA sequencer. The data were analyzed using Genescan 3.1 and Genotyper 2.5 
software (PE Applied Biosystems). Samples with a missing genotype result for FV 
Leiden or FII G20210A were analyzed with another method (Factor V Leiden Kit 
and Factor II (Prothrombin) G20210A Kit with LightCycler® Instrument, Roche 
Diagnostics GmbH, Mannheim, Germany) in Finnish Red Cross Blood Service. 
In addition, positive findings of FV Leiden and FII G20210A mutations were 
confirmed with the latter method. All results were concordant and all markers 
obeyed the Hardy-Weinberg equilibrium.
7.7 Statistical analysis
To test differences between cases and controls, Pearson Chi-Square or Fisher’s 
Exact Test were used for discrete variables. Logistic regression was used to 
estimate crude and adjusted odds ratios (ORs) and their 95% confidence intervals 
(CIs) for dummy variables.
SPSS® version 12.0.1 (SPSS Inc. Chicago, Illinois, USA) in Studies I-II and 
SPSS® version 15.0.1 in Studies III-IV (IBM Corporation, Somers, NY, USA), 
and StatsDirect statistical software version 2.7.3 (StatsDirect Ltd, Cheshire, UK) 
were used for statistical analyses. A two-sided p-value of <0.05 was considered 
statistically significant.
When appropriate, possible confounding was controlled by restriction and 
stratification. Effect modification was explored by observing strata. To control 
for the possible confounding effect of gravidity, primigravid women were studied 
separately in Studies II and IV. To control for the possible effect of multiple 
pregnancy, women with a singleton pregnancy were studied separately in Studies 
III and IV. To control for the heterogeneous pathogenesis of preterm birth in 
Study IV, a subgroup analysis was done of women (cases and controls) with 
pregnancies lasting ≥195 gestational days without stillbirth, pre-eclampsia, IUGR, 
placental abruption, or chorionamnionitis. 
Specifically in Study I, attributable risk (AR) was calculated as follows: AR = Ie 
– I0 [138]. In this context, Ie is the incidence of venous thrombosis in FV Leiden 
carriers and I0 the incidence of venous thrombosis in non-carriers. AR indicates 
the risk for pregnancy-associated venous thrombosis among FV Leiden carriers 
attributable to the FVL. Attributable risk proportion (AR%) was calculated using 
formula AR% = (AR / Ie) x 100 [138]. AR% states what proportion of pregnancy-
associated venous thrombosis among FV Leiden carriers can be attributed to 
the FVL. Population attributable risk (PAR) was calculated as follows: PAR = IT 
– I0 [138]. In this context, IT is the incidence rate of venous thrombosis in the 
whole studied cohort. PAR indicates the risk for pregnancy-associated venous 
thrombosis attributable to the FV Leiden in the population of women with 
pregnancies not ending during the first trimester. Population attributable risk 
proportion (PAR%) was calculated using formula PAR% = (PAR / IT) x 100 [138]. 
PAR% states the proportion of pregnancy-associated venous thrombosis in the 
population attributable to the FVL.
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8 RESULTS
Table 7 summarizes the genotype frequencies of FV Leiden in cases and controls 
in Studies I-IV and presents the overall risk associated with FV Leiden and the 
studied disease entity.
Table 7. Genotype frequencies of FV Leiden in Studies I-IV.






I    Venous thrombosis 34 641
FV Leiden   GG 27 627 11.6 (3.6-33.6)
  GA 6 (17.6) 14 (2.2)
  AA 1 (2.9) 0
II   Pre-eclampsia 248 679
FV Leiden   GG 238 663 1.7 (0.8-3.9)
  GA 10 (4.0) 16 (2.4)
  AA 0 0
III Stillbirth 44 776
FV Leiden   GG 40 756 3.8 (1.2-11.6)
  GA 4 (9.1) 20 (2.6)
  AA 0 0
IV  Preterm birth 324 752
FV Leiden   GG 305 733 2.4  (1.3-4.6)
  GA 19 (5.9) 19 (2.5)
  AA 0 0
Abbreviations: CI, confidence interval
*Carriers of the FV Leiden (heterozygotes and homozygotes) versus wild-type.
# Genotype: GG, wild-type homozygote; GA, FV Leiden heterozygote; AA, FV Leiden homozygote.
The prevalence of FV Leiden was 2.2-2.6% in controls. Excluding the first study, 
controls in Studies II-IV included also women with prior venous thromboses and 
women with other pregnancy complications. In the population sample of 644 
blood donors, the prevalence of FV Leiden was 2.4%.
In Study I, the prevalence of FV Leiden was unequal in older and younger 
controls. The prevalence of FV Leiden was 7.7% (6/78) in controls over the age of 
35 and 1.4% (8/563) in controls under the age of 35 (p=0.009). The result was 
the same when not only eligible but all control candidates (843) were considered 
(8.7% vs. 2.3%, p=0.002)). Neither parity nor gravidity affected the finding.
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8.1 Study I - Pregnancy-associated venous thrombosis
Assessing index pregnancies, FV Leiden was associated with an 11-fold increased 
risk for pregnancy-associated venous thrombosis (OR 11.6, 95% CI 3.6-33.6). 
When analyzing only cases whose first venous thrombosis occurred in association 
with the index pregnancy, FV Leiden was associated with a 6-fold risk (OR 5.8, 
95% CI 1.6-21.8). When only primigravid cases were analyzed, FV Leiden was 
associated with a 9-fold risk (OR 8.7, 95% CI 1.5-50.6).







Controls, n=641 14 (2.2) 1.0 *
Venous thrombosis, n=34 7 (20.6) 11.6 (3.6-33.6)
First venous thrombosis, n=26 3 (11.5) 5.8 (1.6-21.8)
Primigravid women
Controls, n=223 5 (2.2) 1.0 *
Venous thrombosis, n=12 2 (16.7) 8.7 (1.5-50.6)
Abbreviations: CI, confidence interval.
*Reference group.
The risk associated with FV Leiden was modified by blood group, BMI, and age. 
The risk for pregnancy-associated venous thrombosis was 25-fold (OR 25.1, 95% 
CI 6.6-95.4) in women who had FV Leiden and non-O blood group, compared 
with women without FV Leiden and with blood group O. In women with FV Leiden 
and BMI over 30, the risk was 75-fold (OR 75.5, 95 % CI 6.7-846.5, adjusted 
for age), compared with women without the mutation and BMI less than 25. 
In women with FV Leiden and age over 35, the risk was nearly 60-fold (OR 
58.1, 95% CI 4.2-799.7, adjusted for BMI), compared with women without the 
mutation and age less than 25. (See table 4 in Study I.)
In carriers of FV Leiden, 92% (95% CI 80-96) of thromboses were attributable 
to this mutation (AR%). In the whole study population, 19% (95% CI 16-20) of 
thromboses were attributable to FV Leiden (PAR%). (See table 5 in Study I.)
8.2 Study II - Pre-eclampsia
As different risk factors may be associated with different clinical entities of pre-
eclampsia, subgroups were analysed separately. In addition to pre-eclampsia as a 
whole (248 cases), severe pre-eclampsia (168 cases, 68%), early pre-eclampsia 
(77 cases, 31%), and pre-eclampsia with IUGR (53 cases, 21%) were analyzed 
separately. Severe pre-eclampsia included 12 cases with eclampsia. Subgroups 
were partly overlapping. Pre-eclampsia was recurrent in 18% of multigravid cases.
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As pre-eclampsia is particularly a disease of the first pregnancy, primigravid 
subjects were analyzed separately. Of the 143 primigravid cases, 99 (69%) had 
severe pre-eclampsia, 44 (31%) had early pre-eclampsia, and 29 (20%) had pre-
eclampsia with IUGR. Subgroups were partly overlapping.
Table 9 shows the association of FV Leiden with subgroups of pre-eclampsia. The 
point estimates of the risk were 1.5-2.5 when all women were analyzed and 2.4-
3.4 when primigravid women were considered. However, these associations were 
not statistically significant.






Controls, n=679 16 (2.4) 1.0 *
Pre-eclampsia, n=248 10 (4.0) 1.7 (0.8-3.9)
Severe pre-eclampsia, n=168   6 (3.6) 1.5 (0.6-4.0)
Early pre-eclampsia, n=77   4 (5.2) 2.3 (0.7-7.0)
Pre-eclampsia and IUGR, n=53   3 (5.7) 2.5 (0.7-8.8)
Primigravid women
Controls, n=232   5 (2.2) 1.0 *
Pre-eclampsia, n=143   8 (5.6) 2.7 (0.9-8.4)
Severe pre-eclampsia, n=99   5 (5.1) 2.4 (0.7-8.5)
Early pre-eclampsia, n=44   3 (6.8) 3.3 (0.8-14.4)
Pre-eclampsia and IUGR, n=29   2 (6.9) 3.4 (0.6-18.2)
Abbreviations: CI, confidence interval; IUGR, intrauterine growth restriction.
*Reference group.
8.3 Study III – Stillbirth
Of the unexplained stillbirths in 44 cases, 12 (27%) occurred during 22-27 weeks 
of gestation (early) and 32 (73%) occurred at or after 28 weeks of gestation 
(late). The frequency of FV Leiden did not differ in these two groups (early 1/12, 
8% vs. late 3/32, 9%). Late unexplained stillbirth and unexplained stillbirth with 
placental lesions (placental infarction or placental abruption) were analyzed 
separately. As twin pregnancy is a major risk factor for stillbirth, women with 
a singleton pregnancy were analyzed separately. Stillbirth was recurrent in one 
case. Of the primigravid women, none of the 13 cases and 7 of the 265 controls 
(2.6%) were carriers of FV Leiden.
Table 10 shows the association of FV Leiden with unexplained stillbirth. FV 
Leiden was associated with a 3-fold to 4-fold risk, whether analyzing all 
unexplained stillbirths or late unexplained stillbirths in all pregnancies or in 
singleton pregnancies. The association seemed to be pronounced when assessing 










Controls, n=776 20 (2.6) 1.0 *
Unexplained stillbirth #, n=44 4 (9.1) 3.8 (1.2-11.6)
Late unexplained stillbirth #  
(≥ 28 weeks of gestation), n=32 3 (9.4) 3.9 (1.1-13.9)
Unexplained stillbirth #  
with placental lesions ¤, n=9 2 (22.2) 10.8 (2.1-55.3)
Singleton pregnancies
Controls, n=762  20 (2.6) 1.0 *
Unexplained stillbirth #, n=39 3 (7.7)   3.1 (0.9-10.9)
Late unexplained stillbirth #  
(≥ 28 weeks of gestation), n=29 3 (10.3) 4.3 (1.2-15.3)
Unexplained stillbirth #
with placental lesions ¤, n=9 2 (22.2) 10.6 (2.1-54.3)
Abbreviations: CI, confidence interval.
* Reference group.
# Chromosome anomalies, malformations, infections, and umbilical cord complications excluded.
¤  Placental infarction or placental abruption.
8.4 Study IV – Preterm birth
Of the 324 cases, 78 (24%) had birth before 32 weeks of pregnancy (early 
preterm birth) and 246 (76%) had birth at 32-36 weeks of pregnancy (late 
preterm birth). Preterm birth was recurrent in 22% of multigravid cases. As 
pathophysiology of early and late preterm birth may differ, they were analyzed 
also separately.
FV Leiden was significantly associated with preterm birth (OR 2.4) and especially 
with late preterm birth (OR 2.9), but not with early preterm birth (OR 1.0). 
The association was significant also when primigravid cases and controls were 
analyzed (OR 3.3) and when cases and controls without stillbirth, pre-eclampsia, 
IUGR, placental abruption, or chorionamnionitis were analyzed (OR 2.6). Results 
are summarized in table 11.
FV Leiden was associated with preterm birth whether there had been premature 
rupture of membranes or not (OR 2.8, 95% CI 1.01-7.7; and OR 2.2, 95% CI 
1.1-4.6) and when indicated deliveries (induced labour or cesarean delivery) 
were excluded from cases and controls (OR 3.6, 95% CI 1.7-7.8).
As a twin pregnancy predisposes to preterm birth, singleton pregnancies were 
analyzed separately. The results for singleton pregnancies were similar to the 
results for all pregnancies (table 11).
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When primigravid women with singleton pregnancies without stillbirth, pre-
eclampsia, IUGR, placental abruption, or chorionamnionitis were analyzed, FV 
Leiden was associated with nearly a 5-fold risk for late preterm birth (OR 4.7, 
95% CI 1.5-15.3).







Controls, n=752 19 (2.5) 1.0 *
Preterm birth, all, n=324 19 (5.9) 2.4 (1.3-4.6)
Early preterm birth  
(<32 weeks of gestation), n=78 2 (2.6) 1.0 (0.2-4.4)
Late preterm birth  
(32-36 weeks of gestation), n=246 17 (6.9) 2.9 (1.5-5.6)
Primigravid controls, n=262 6 (2.3) 1.0 *
Primigravid cases, n=112 8 (7.1) 3.3 (1.1-9.7)
Controls without complications #, n=705 17 (2.4) 1.0 *
Preterm birth without other 
complications #, n=229 14 (6.1) 2.6 (1.3-5.4)
Singleton pregnancies
Controls, n=742  19 (2.6) 1.0 *
Preterm, all, n=279 18 (6.5) 2.6 (1.4-5.1)
Early preterm birth  
(<32 weeks of gestation), n=69 2 (2.9) 1.1 (0.3-5.0)
Late preterm birth  
(32-36 weeks of gestation), n=210 16 (7.6) 3.1 (1.6-6.2)
Primigravid controls, n=261 6 (2.3) 1.0 *
Primigravid cases, n=91 7 (7.7) 3.5 (1.2-10.8)
Controls without complications #, n=697 17 (2.4) 1.0 *
Preterm birth without other 
complications #, n=196 14 (7.1) 3.1 (1.5-6.4)
Abbreviations: CI, confidence interval.
* Reference group.
# Women with pregnancies lasting ≥195 gestational days and without stillbirth, pre-eclampsia, IUGR, 




8.5 FII G20210A in Studies I-IV
Table 12 summarizes genotype frequencies of FII G20210A in cases and controls 
in Studies I-IV and presents the overall risk associated with FII G20210A and the 
studied disease entity.
Table 12. Genotype frequencies of FII G20210A in Studies I-IV.






Venous thrombosis 34 641
FII G20210A   GG 33 635 3.2 (0.07-27.6)
   GA 1 (2.9) 6 (0.9)
   AA 0 0
Pre-eclampsia 248 679
FII G20210A   GG 244 673 1.8 (0.5-6.6)
   GA 4 (1.6) 6 (0.9)
   AA 0 0
Stillbirth 44 776
FII G20210A   GG 44 769 -
   GA 0 7 (0.9)
   AA 0 0
Preterm birth 324 752
FII G20210A   GG 323 745 0.3  (0.04-2.7)
   GA 1 (0.3) 7 (0.9)
   AA 0 0
Abbreviations: CI, confidence interval.
* Carriers of the FV Leiden (heterozygotes and homozygotes) versus wild-type.
# Genotype: GG, wild-type homozygote; GA, F II G20210A heterozygote; AA, F II G20210A homozygote.
8.6 Other polymorphisms than FV Leiden and FII G20210A in Studies I-IV
The genotype frequencies of FV A4070G, PROC T8553G, MTHFR C677T, TFPI C536T, 
and FXIII V34L in Studies I-IV are presented in table 2 of each study (see original 
articles). In this study population, none of them was significantly associated with 
an increased risk for venous thrombosis, pre-eclampsia, stillbirth, or preterm birth. 
FXII V34L was not associated with a decreased risk for these disease entities.
8.7 Blood group in Studies I-IV
The prevalence of ABO and Rh blood groups in the Finnish population is as follows: 
O 31%, A 44%, B 17%, AB 8%, Rh D positive 87%, and Rh D negative 13%. Table 13 
summarizes the distribution of ABO blood groups in cases and controls for each study.
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Venous thrombosis 34 641
O 7 (20.6) 207 (32.3)
A 18 (52.9) 278 (43.4)
B 6 (17.6) 117 (18.3)
AB 3 (8.8) 39 (6.1)
Blood group O 7 (20.6) 207 (32.3) 1.0 *
Blood group Non-O 27 (79.4) 434 (67.7) 1.8 (0.8-4.3)
Pre-eclampsia 248 679
O 72 (29.0) 217 (32.0)
A 104 (41.9) 294 (43.3)
B 40 (16.1) 124 (18.3)
AB 32 (12.9) 44 (6.5)
Blood group Non-AB 216 (87.1) 635 (93.5) 1.0 *
Blood group AB 32 (12.9) 44 (6.5) 2.1 (1.3-3.5)
Stillbirth 44 776
O 20 (45.5) 243 (31.3)
A 15 (34.1) 337 (43.4)
B 7 (15.9) 140 (18.0)
AB 2 (4.5) 56 (7.2)
Blood group Non-O 24 (54.5) 533 (68.7) 1.0 *
Blood group O 20 (45.5) 243 (31.3) 1.8 (0.99-3.4)
Preterm birth 324 752
O 97 (29.9) 239 (31.8)
A 134 (41.4) 333 (44.3)
B 65 (20.1) 131 (17.4)
AB 28 (8.6) 49 (6.5)
Blood group O 97 (29.9) 239 (31.8) 1.0 *
Blood group Non-O 227 (70.1) 513 (68.2) 1.1 (0.8-1.4)





Well-planned and conducted case-control studies can provide valuable information 
on the association between a risk factor and disease and they can be reliably 
used to test epidemiologic hypothesis [48]. A nested case-control study is a 
modification of a cohort study, in which only cases and a sample of controls in a 
fixed cohort are assessed in detail [8]. This nation-wide population-based nested 
case-control study assessing FV Leiden as a risk factor for selected pregnancy 
complications in Finland was conducted according to acknowledged principles of 
epidemiological studies. The adequate national registers provided exceptionally 
good preconditions.
9.1 Ethnic background
In genetic association studies, false positive and false negative associations may 
be possible due to population structure [50]. In this study, this was avoided – 
at least according to present knowledge. Although the Finnish population is not 
as genetically homogeneous as it was even lately thought to be [139,140], the 
cases and controls are of the same ethnic Caucasian origin and come equally 
from different parts of Finland. Genetic differences between European subgroups 
are smaller than between subpopulations of other ethnic origins [50]. Similarly to 
other populations of Caucasian origin, FV Leiden is prevalent in Finland, although 
not as frequent as in some European countries.
9.2 Prevalence of FV Leiden in Finland
The prevalence of FV Leiden was 2.2-2.6% in controls of Studies I-IV, and 2.4% 
in the population sample of 644 blood donors. These numbers are in agreement 
with other Finnish materials, where the prevalence of FV Leiden has been 2.1-
2.9% in controls [141,142].
The reason for the post hoc finding of increased prevalence of FV Leiden in 
controls over the age of 35 is unclear. One could hypothesize that it may be due 
to improved embryo implantation [43] associated with FV Leiden in women whose 
fertility is otherwise decreasing. Improved embryo implantation is also supported 
by an observation of lower miscarriage-rate during the first trimester in FV Leiden 
carriers with an overall similar miscarriage-rate [44]. It is unlikely that FV Leiden 
would have affected the decision of controls to participate and the participation- 
rate was the same in every age-group.
9.3 Bias and confounding
Bias is defined as any systematic error that may cause an incorrect estimate 
of the association between exposure and outcome [143]. Selection bias was 
avoided by using the Hospital Discharge Register in the identification of cases and 
controls. Detection bias is unlikely, as FV Leiden has most certainly not influenced 
the reporting rate of complications to the Hospital Discharge Register. Information 
bias was minimized by collecting data from medical records and questionnaires 
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on standardized forms blinded for laboratory results. In general, cases with 
pregnancy complications may remember their pregnancy in more detail than 
controls with uneventful pregnancy [143]. However, in this study, recall bias is of 
less importance as outcomes were gathered from the Hospital Discharge Register 
and verified from medical records, and as exposure (FV Leiden) is inherited 
and was assessed by laboratory analysis. Missing cases may bias absolute risk 
estimates, but their impact on relative risks is minor.
Factors that are associated with both the exposure (FV Leiden) and outcome 
(studied disease entity) are confounding factors when the factor is not on 
the causal pathway [144]. In other words, confounding factor increases (or 
decreases) independently the risk for outcome, being at the same time associated 
with exposure. For example, previous venous thrombosis increases the risk for 
future venous thrombosis, but because FV Leiden may increase the risk for both 
of these thromboses, i.e., be causally associated, previous venous thrombosis is 
not a true confounding factor. 
9.4 Strengths of the study
The strengths of the study are the population-based setting, large number of 
consecutive pregnancies within a short time-period (same diagnostic criteria 
and diagnostic tools), cases and controls from the same pregnant population of 
Caucasian origin, and strict diagnostic criteria. The laborious strategy of checking 
all medical records allowed exclusion of false positive findings in cases and false 
negative findings in controls. This also made subdivision of cases possible.
It is not likely that the pre-pregnancy knowledge of FV Leiden has influenced 
the results, because at the beginning of the study, only four hundred women of 
childbearing age were known to carry FV Leiden in the whole country. Presently, 
this kind of study population would hardly be obtainable.
The genotyping was performed at the Finnish Genome Center as a collaboration 
project. Genotyping methods for the seven polymorphisms were set up by Anna 
Rautanen, and were included in her thesis [137]. On average, the final success 
rate of genotyping these polymorphisms was very high, 99.5% [137]. In addition, 
all positive findings of FV Leiden and F II G20201A were confirmed with a method 
validated for diagnostic purposes in the Finnish Red Cross Blood Service. All 
results were concordant and all markers obeyed the Hardy-Weinberg equilibrium. 
9.5 Weaknesses of the study
The study design did not allow assessment of fetal (paternal) genes in association 
with pregnancy complications. In case of prematurity, it seems that heritability of 
preterm birth is mostly transmitted through maternal genes and fetal (paternal) 
genotype is less important [145]. Due to the study design, the assessment of 
the risk for recurrent venous thrombosis, pre-eclampsia, stillbirth, or preterm 
birth was not possible. The family history of studied disease entities could not be 
reliably assessed.
Despite of the large cohort of pregnant women, the number of venous thrombosis 
cases and stillbirth cases was low. This is due to the rarity of these conditions and 
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all cases were invited to the study. Instead, pre-eclampsia and preterm birth are 
so common that only some of the cases were invited.
Participation rate is one of the problematic issues in epidemiologic studies. In this 
study, participation rate was relatively low among controls (44-51%). Considering 
the cases, participation rate was especially low among cases with stillbirth (54%), 
which may be due to strong emotions linked to the devastating occurrence. The 
cause of the low participation rate among cases with preterm birth (53%) can 
only be speculated. It may be due to severe health consequences stemming 
from prematurity in the infant, or, in the case of very late preterm birth, no 
consequences at all diminishing the motivation to participate. However, it is 
not likely that any factor connected to FV Leiden would have caused cases and 
controls to participate differently.
9.6 Missing and false positive diagnoses in the Hospital Discharge 
Register
It is possible that some of the studied diagnoses – especially preterm birth, but 
for some extent also pre-eclampsia – may have been omitted from the three 
diagnoses reported in the Hospital Discharge Register if the pregnancy had 
been associated with several complications. It seems more unlikely that venous 
thromboembolism or stillbirth would have been unreported. In addition, possible 
misclassification or miscoding of diagnoses cannot be excluded. In the case of 
pre-eclampsia and preterm birth, which are both common, the sample size of 
cases would nevertheless have been restricted. It is unlikely that the studied 
variables (e.g. FV Leiden) would have influenced possible misclassification 
or reporting rate of studied diagnoses to the register. The use of the National 
Medical Birth Register (maintained by the National Institute for Health and 
Welfare) in identification of preterm births and stillbirths could have minimized 
the risk for missing diagnoses.
The potentially dangerous bias caused by false positive diagnoses in cases 
was avoided by reviewing the medical records. Systematic scrutiny for false 
negative cases, i.e., women with studied clinical entities without proper ICD-code 
in the Hospital Discharge Register, would not have been feasible. This kind of 
misclassification would also have only a minor impact on the results.
The bias due to non-validated registry-based diagnoses is a known source of error 
in epidemiological studies [146]. Checking all medical records proved crucial, 
because 28% of the diagnoses of venous thrombosis in the Hospital Discharge 
Register were actually not associated with the index pregnancy, and 40% of pre-
eclampsia did not fulfil the strict diagnostic criteria used in this study. 
In this material, many false positive ICD-10 codes for venous thromboembolism 
were due to a past venous thrombosis instead of an acute thrombosis associated 
with the index pregnancy. The ICD-10 classification does not include a separate 
code for past thrombosis (status post thrombosis), which is often recorded as 
diagnosis for example when prophylactic anticoagulation is started. This appears 
to be a common source of false positive diagnoses also observed by others [147]. 
Very strict criteria for pre-eclampsia were used. Therefore, it is possible that 
some cases with mild true pre-eclampsia have been excluded due to a lack of 
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documentation in the medical records. Additionally, some mild pre-eclampsia 
cases may have been registered with other ICD-codes (e.g. pregnancy induced 
hypertension). In this study, missing cases are less important than false positive 
cases would have been. In case of severe pre-eclampsia, misreporting seems 
more unlikely. In a Danish study on the validity of registry diagnoses of pre-
eclampsia, 95% of true pre-eclampsia cases were reported in the registry, but 
only about 70% were classified correctly as mild or severe pre-eclampsia [148]. 
9.7 Study I – Pregnancy-associated venous thrombosis
In this study, FV Leiden was associated with a 6 to 11-fold risk for pregnancy-
associated venous thrombosis. Although FV Leiden was a major risk factor, the 
overall absolute risk of VTE for a FV Leiden carrier was estimated to be only 318 
per 100,000. That is, one of 314 carriers would have thrombosis in association 
with pregnancy. On the population level, FV Leiden was estimated to be 
responsible for 19% of pregnancy-associated thromboses. The risk resulting from 
the combination of FV Leiden and older maternal age was additive, whereas the 
interaction of FV Leiden with BMI, and FV Leiden with non-O blood group resulted 
in a more than additive risk.
The risk associated with FV Leiden was of the same magnitude as in other 
studies (OR 3.7-18.3, see references in tables 1 and 2), although the studies 
vary in many respects. In a study by McColl et al. [59], the absolute risk of a 
carrier of FV Leiden for pregnancy-associated venous thrombosis was estimated 
to be slightly lower than in this study, 1 in 437. At the moment, except for the 
present study, no other studies estimating population attributable risk proportion 
of FV Leiden for pregnancy-associated venous thrombosis exist. In the general 
population, a study on White men and women aged 18-65 years estimated that 
6.6% of VTE episodes were attributable to FV Leiden [149].
Pregnancy-associated venous thromboembolism is rare, occurring usually in 
less than 1 in 1,000 pregnancies in western countries [58-62]. In this study, 
objectively verified VTE was found in 34 per 100,000 pregnancies. If thromboses 
in the index pregnancies occurred at the same frequency in participants and 
non-participants, due to 80% participation rate, this study missed nine true 
pregnancy-associated venous thromboses. Taking this into account, the incidence 
of 43 per 100,000 is still less than in other studies where the incidence of 
objectively verified venous thromboembolism has ranged from 61 per 100,000 
deliveries in mainly Hispanic population [62] to 85 per 100,000 in Danish 
population [60], and to 86-123 per 100,000 in UK [40,59]. In studies with 
register-based diagnoses, the incidence has been 85 per 100,000 deliveries in 
the UK (23% non-European origin) [60,61], and in the USA, 107 per 100,000 in 
Asian women, 125 per 100,000 in Hispanic women, 175 per 100,000 in White 
women, and 264 per 100,000 in Black women [150]. The detected incidence of 
pregnancy-associated VTE varies in different studies probably due to differences 
in the diagnostic tools, due to whether the incidence is based on register-based 
data or data from medical records, due to whether the incidence is calculated for 
pregnancies (as in this study) or for deliveries (as in most of the other studies) 
and due to true differences in the incidence of VTE in different populations. It 
seems unlikely that deep venous thromboses, pulmonary emboli, and cerebral 




In the 70 reviewed medical records, diagnosis of any venous thrombosis was 
recorded in association with the index pregnancy. However, in 20 women, the 
venous thrombosis had occurred clearly before the index pregnancy. These 
women along with women with non-objectively diagnosed thrombosis (4), and 
women with superficial venous thromboses (12) were excluded from this study. 
Therefore, without proper assessment of the diagnoses by reviewing the medical 
records, the results could have been strongly misleading. In a Danish study 
evaluating discharge diagnoses of VTE during pregnancy and puerperium, the 
positive predictive value was 79% when focusing on confirmed VTE in association 
with pregnancy [146]. The authors concluded that diagnoses are recommended 
to be verified by a review of the medical records in epidemiological studies 
assessing pregnancy-related venous thrombosis. 
 
Even if FV Leiden can be regarded as an established risk factor for venous 
thrombosis, there still is need for well-designed large prospective population-
based studies to further clarify the absolute risk of pregnancy-related venous 
thrombosis in non-selected carriers of FV Leiden.
9.8 Study II – Pre-eclampsia
In this study, FV Leiden was associated with a 1.7-fold risk for pre-eclampsia, 
but the association was not statistically significant. The study would have had 
sufficient power (80% power, 5% α-error) to detect a 3-fold risk associated with 
FV Leiden.
The point estimate of the risk in this study is in the range of other studies. In 
three meta-analyses of mainly case-control studies [79,92,93], FV Leiden has 
been associated with about a 2-fold risk whether all or only severe pre-eclampsia 
has been considered, or whether heterozygous and homozygous carriers of FV 
Leiden have been analyzed combined or separately. In one meta-analysis of six 
cohort studies, FV Leiden was associated with a 1.5-fold risk for pre-eclampsia 
[96]. On the contrary, the meta-analysis of nine prospective cohort studies by 
Rodger et al. did not show significant association between FV Leiden and pre-
eclampsia, the pooled OR being 1.2 [3], as did not the most recent nested case-
control study by Kahn et al. [97]. 
In the whole study population, 1,084 of 100,000 (1.1%) women had the 
diagnosis of pre-eclampsia, eclampsia, or both in the Hospital Discharge 
Register. This incidence is somewhat lower than the incidence of 1.5-2.9% 
in recent European studies where diagnoses were verified from the medical 
records [40,148,151,152]. This may be due to the fact that only three diagnoses 
per hospital care period are recorded in the Hospital Discharge Register. For 
comparison, in the Medical Birth Register, which includes ten diagnoses from 
the period of pregnancy and ten diagnoses from the period of delivery, the 
incidence of pre-eclampsia (including eclampsia) has been 2.0% in 2006 and 
2007 (personal communication, Eija Vuori, October 2008). It is possible that 
pre-eclampsia may have been omitted from the three diagnoses in the Hospital 
Discharge Register if the pregnancy had also been associated with several other 
complications and if the pre-eclampsia had been mild. Mild pre-eclampsia may 
also have been miscoded. The difference in incidence rates may also be explained 
by different definitions of pre-eclampsia, different methods of collecting data, 
whether only primigravid women were included, and whether the incidence was 
proportioned for pregnancies or for deliveries.
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From the clinical point of view, mild pre-eclampsia is usually more common than 
severe pre-eclampsia. In this study, however, 68% of the cases had severe pre-
eclampsia. This may be due to the reasons already described and due to the 
very strict criteria for pre-eclampsia used in this study, which may have led to 
the exclusion of some true mild cases of pre-eclampsia if the documentation in 
the medical records were insufficient. The finding is not unique, as in a recent 
study by Klemmensen et al. [148], 63% of strictly defined pre-eclampsia cases 
were severe. The incidence of severe pre-eclampsia is in agreement with present 
knowledge, which supports the idea of mild pre-eclampsia being underreported. 
In this study, the estimated incidence of severe pre-eclampsia in the whole study 
population was 442 per 100,000 pregnancies, which is in line with incidences of 
516 per 100,000 [153] and 458 per 100,000 (mainly White) [154] reported in 
the UK. 
Despite the limitations of meta-analyses and individual studies, FV Leiden seems 
not to be a major risk factor for pre-eclampsia. However, as pre-eclampsia is 
a very heterogeneous disease entity, it may be worth further studying well-
specified clinical subgroups separately in ethnically homogeneous populations to 
minimize the risk of not observing any true association with FV Leiden.
9.9 Study III – Stillbirth
FV Leiden was associated with a 3-fold risk for unexplained stillbirth in all and in 
singleton pregnancies, and a 4-fold risk for late unexplained stillbirth. About one 
in ten of the mothers with unexplained stillbirth was a carrier of FV Leiden.
Three meta-analyses [79,92,106] have shown similar, a 2- to 3-fold risk 
for association between FV Leiden and late fetal loss. However, studies vary 
considerably regarding the selection of cases and controls, definition of stillbirth, 
and what other possible causes of stillbirth have been excluded. Published case-
control studies of unexplained stillbirth (table 3) have mainly found a statistically 
significant association with FV Leiden, but retrospective cohort studies (table 4) 
of all stillbirths mostly have not. In many cohort studies [86,115,116,118], 
the stillbirth rate in FV Leiden non-carriers has been unexpectedly high, 2-5% 
(6-11% in FV Leiden carriers) compared with the estimated rate of 0.4-0.7% 
in developed countries [98]. Two of these studies [115,116] assessed cohorts 
from thrombophilic families. The only prospective antenatal cohort study [105], 
despite its limitations of heterogenic ethnicity and small number of unexplained 
stillbirths, had a reliable stillbirth rate (0.35%) and found nearly a 9-fold risk 
associated with FV Leiden. 
In the whole study population, 224 of 100,000 women had the diagnosis 
of stillbirth in the Hospital Discharge Register. This incidence of 2.2 per 1,000 
pregnancies is somewhat lower than the estimated incidence of 4.2-6.8 per 
1,000 deliveries in developed countries [98], but it is in agreement with the low 
stillbirth rate in the Nordic countries [99]. The review of medical records of the 
120 participants revealed that in 20% of cases fetal death had occurred before 
22nd gestational week, or the diagnosis was miscoded. The participation rate was 
relatively low, which may be due to strong emotions associated with the stillbirth. 
However, it is not likely that FV Leiden or some factor associated with it would 
have affected the decision of participation.
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Since association of FV Leiden with stillbirth varies in different studies, it is 
likely that other factors modulate the risk for placenta-mediated pregnancy 
complications, such as fetal loss and pre-eclampsia. Recent data from mouse 
models have shown that, at least in mice, fetal thrombophilia expressed on 
trophoblast cells increases the risk for fetal loss in carriers of FV Leiden [155]. 
Also, the mechanism by which thrombophilia increases the risk for fetal loss is 
not always via placental thrombosis, but through the impairment of placental 
growth and morphogenesis [155]. 
The “ultimate truth” about the strength of association between FV Leiden and 
unexplained stillbirth remains to be seen with results from future prospective 
cohort studies. Future studies should preferably analyze both maternal and fetal 
(paternal) genotypes to assess factors that modify the risk associated with FV 
Leiden. 
9.10 Study IV – Preterm birth
In this study, FV Leiden was associated with a 2.5-fold risk for preterm birth in 
all as well as in singleton pregnancies. FV Leiden was especially associated with 
late preterm birth (a 3-fold risk) but not with early preterm birth. FV Leiden was 
consistently associated with an increased risk also in subgroup analyses of women 
with a singleton pregnancy, women without other pregnancy complications, and 
women with spontaneous preterm delivery.
At present, this study is the largest population-based study on the association 
between FV Leiden and preterm birth. Other studies assessing the association are 
few and mostly small (tables 5 and 6). Differences in study populations, ethnic 
backgrounds, and exclusion criteria make comparison with the present study 
difficult.
The three prior studies with positive findings may be considered preliminary. 
The first positive association came from a study of very low birth weight infants 
[125], but could not be confirmed later by the same group [130]. The second 
positive observation came from 50 women with preterm birth among whom 
the prevalence of FV Leiden was higher than in general population [126]. The 
third positive result came from the only prospective cohort study existing today, 
albeit from a subanalysis of women with preterm birth and evidence of placental 
hemorrhage [127].
Also the four studies with negative findings have limitations that restrict the 
generalizability of the results. First, the study population being other than 
Caucasian [128], or ethnic background not being reported [129,131,132]. 
Second, studying only a subgroup of preterm birth: women with VLBW preterm 
infants [130], or women with preterm infants admitted to neonatal intensive care 
unit and women with term infants admitted to neonatal intensive care unit used 
as controls [129]. Third, being very small [131]. In an otherwise representative 
study [112], the prevalence of FV Leiden was very variable in matched controls 
of different disease entities (2 to 8.2%) leading to a very high risk estimate for 
stillbirth but resulting in no association with preterm birth.
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The incidence of preterm birth is about 5% in Finland [99]. However, in the 
whole study population, only 1,402 of 100,000 (1.4%) women had the diagnosis 
of preterm birth in the Hospital Discharge Register. As in the case of pre-
eclampsia, this may be due to the fact that only three diagnoses per a hospital 
care period are recorded in the Hospital Discharge Register. It is possible that 
preterm birth may have been omitted from the three diagnoses in the Hospital 
Discharge Register if the pregnancy had also been associated with several other 
complications, or if the preterm birth had occurred near term. The participation 
rate of preterm birth cases was relatively low. Speculatively, this may be due to 
devastating consequences of prematurity, or no consequences at all diminishing 
the motivation to participate. It is, however, very unlikely that FV Leiden would 
have affected the reporting rate to the register or the decision of cases to 
participate. 
Preterm birth is a very heterogeneous entity, and the pathophysiology behind it 
may differ in early and late preterm birth [119]. In this study, FV Leiden was 
associated with late but not with early preterm birth. Early preterm birth was 
associated significantly more often with chorionamnionitis, premature rupture 
of membranes, and IUGR (data not shown). Uterine anomaly was also more 
common in early preterm birth, although not statistically significantly. The 
prevalence of pre-eclampsia, in vitro fertilization, and twin pregnancy was equal 
in early and late preterm birth. As inflammation is involved in both term and 
preterm delivery [5], and as coagulation and inflammation are interrelated [6], it 
is tempting to speculate that FV Leiden (thrombophilia) through excess thrombin 
production would lead to preterm birth by prematurely activating inflammatory 
mechanisms that normally induce term labour.
As no unselected prospective studies on the association of FV Leiden with preterm 
birth exist, further well-designed, preferably prospective studies are needed to 
establish the association in Caucasian population. 
9.11 Does FV Leiden have causal influence on pregnancy 
complications?
Hill’s criteria from 1965 have been widely used to evaluate the causality of a 
risk factor for a disease, although it has been said that in his own opinion none 
of these viewpoints can absolutely prove or disprove a causal effect [156]. Hill’s 
criteria are: 1) strength of association, 2) consistency of observed association, 
3) temporality, 4) specificity, 5) biologic plausibility, 6) biologic gradient, 7) 
coherence, 8) analogy, and 9) experiment.
9.11.1 FV Leiden as risk factor for pregnancy-associated venous thrombosis
1) In this study, FV Leiden was associated with an 11-fold increased risk for 
pregnancy-associated thrombosis and a 6-fold risk for first venous thrombosis. 
Association can be considered strong.
2) Association of FV Leiden with pregnancy-associated venous thrombosis has 
been consistent. In other studies FV Leiden has been associated with a 4.5-fold 
to 18-fold risk. In a pooled analysis, the risk was 8-fold.
3) As FV Leiden is inherited, temporal relationship exists.
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4) All carriers of FV Leiden do not get venous thrombosis in association with 
pregnancy or even in their life-time. On the other hand, FV Leiden may also be 
associated with other disease entities. Venous thrombosis has many other risk 
factors as well and FV Leiden is not necessary for venous thrombosis to occur.
5) Biologic plausibility exists as FV Leiden changes the structure of factor V 
making it resistant to protein C and unable to function as a cofactor for protein 
C. These functional changes lead to increased formation of thrombin.
6) Homozygotes were too rare to assess biologic gradient. However, dose-effect 
has been demonstrated in other studies, in which the risk for thrombosis has 
been much higher in homozygotes than in heterozygotes (34-fold vs. 8-fold).
7) FV Leiden as a risk factor for pregnancy-associated venous thrombosis does 
not contradict the present knowledge of FV Leiden increasing the risk for venous 
thrombosis in a biologically plausible way.
8) In addition, other thrombophilias have been found to increase the risk for 
pregnancy-associated venous thrombosis.
9) Anticoagulant prophylaxis during pregnancy and puerperium is proven to 
protect against pregnancy-associated thrombosis.
The point 4 is not entirely fulfilled, but there is no doubt that FV Leiden causally 
increases the risk for venous thrombosis. However, FV Leiden is only one of 
the risk factors for the multifactorial disease of venous thrombosis. Thrombosis 
occurs when the effect of simultaneous risk factors reaches a certain trigger 
point.
 
9.11.2 FV Leiden as risk factor for pre-eclampsia, stillbirth, and preterm birth
1) In this study, FV Leiden was associated with trend of a 1.7-fold risk for pre-
eclampsia, 3-fold risk for unexplained stillbirth, and 2.5-fold risk for preterm 
birth. Association can be considered weak for pre-eclampsia and modest for 
stillbirth and preterm birth.
2) Association of FV Leiden with these placenta-mediated pregnancy complications 
has been inconsistent, possibly due to the heterogeneity of the studies.
3) As FV Leiden is inherited, temporal relationship exists.
4) All carriers of FV Leiden do not get placenta-mediated complications. On the 
other hand, FV Leiden is also associated for example with venous thrombosis. 
Placenta-mediated pregnancy complications have heterogeneous origin with 
unknown pathophysiological mechanisms, and FV Leiden is not necessary for 
them to occur.
5) Biologic plausibility exists as FV Leiden changes the structure of factor V 
making it resistant to protein C and unable to function as a cofactor for protein C. 
These functional changes lead to an increased formation of thrombin. Coagulation 
and inflammatory mechanisms are closely interrelated and it is possible that 




6) Rarity of homozygotes hampers the assessment of biologic gradient.
7) FV Leiden as a risk factor for placenta-mediated pregnancy complications does 
not contradict the present knowledge of FV Leiden increasing the risk for venous 
thrombosis in a biologically plausible way.
8) Other thrombophilias (especially antiphospholipid antibodies) have also been 
suggested to increase the risk for placenta-related pregnancy complications. 
9) Anticoagulant prophylaxis during pregnancy and puerperium has not been 
proven to prevent placenta-mediated pregnancy complications. Trials are 
ongoing.
As concluded by Rodger et al. [157], causality between FV Leiden and placenta-
mediated pregnancy complications has not been proven. However, with the 
present knowledge, the modifying effect of FV Leiden cannot be ruled out. 
A mouse model has given novel experimental support to the idea of causality 
[158]. In that experiment, fetal gene defects expressed in trophoblast cells of the 
placenta modified the risk of fetal loss in FV Leiden carriers [158]. 
It can be noted that the risk associated with FV Leiden is consistently much higher 
for venous thrombosis than for specific pregnancy complications. This difference 
in the strength of association may be a sign of different pathophysiological 
mechanisms behind these disease entities.
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10 CONCLUSIONS AND FUTURE PERSPECTIVES
This large population-based nested case-control study showed FV Leiden to be a 
clear risk factor for many pregnancy complications. The study was possible due 
to the adequate national registers, due to legislation allowing the use of registers 
in research, and due to positive attitude of the Finnish women towards research. 
Checking all medical records proved crucial for reliable results. The codes for 
venous thrombosis and pre-eclampsia in the Hospital Discharge Register, in 
particular, included false positive diagnoses considering the diagnostic criteria 
used in this study.
As expected, FV Leiden was a strong risk factor for pregnancy-associated venous 
thrombosis. Maternal carriage of FV Leiden was associated with an 11-fold risk. 
When analyzing only cases with the first venous thrombosis, FV Leiden was 
associated with a 6-fold risk. The risk was multiplied when the carriage of FV 
Leiden was associated with non-O blood group, BMI over 30 kg/m2, or age over 
35 years. These results suggest interaction between FV Leiden and common risk 
factors for venous thrombosis. In the whole study population, 19% of thromboses 
were attributable to FV Leiden. The results confirmed and extended prior 
results of the association between FV Leiden and pregnancy-associated venous 
thrombosis.
When evaluating pre-eclampsia, FV Leiden was associated with a 1.7-fold risk. 
The point estimates of the risk in subgroups of pre-eclampsia were 1.5-2.5 when 
all women were analyzed and 2.4-3.4 when primigravid women were considered. 
However, these associations were not statistically significant. In conclusion, the 
results suggest that the association between FV Leiden and pre-eclampsia, if any, 
is weak.
Novel information was gained especially on unexplained stillbirth and preterm 
birth. When evaluating unexplained stillbirth, FV Leiden was associated with over 
a 3-fold risk. FV Leiden was especially associated with late unexplained stillbirth 
with about a 4-fold risk in both all and singleton pregnancies. When evaluating 
preterm birth, FV Leiden was associated with over a 2-fold risk. FV Leiden was 
especially associated with late preterm birth with about a 3-fold risk. When 
primigravid cases and controls were analyzed, the risk was about 3-fold. When 
analysis was restricted to cases and controls without stillbirth, pre-eclampsia, 
IUGR, placental abruption, or chorionamnionitis, the risk associated with FV 
Leiden was still over 2-fold. In conclusion, the results show that FV Leiden is 
associated with an increased risk for both unexplained stillbirth and preterm birth 
but is not the major risk factor for these disease entities.
The results are in accordance with the current guidelines for screening and 
prophylaxis. Future studies are needed to show if the association between FV 
Leiden and specific pregnancy complications is causal and if prophylaxis with 
LMWH has a beneficial effect. Until then, screening for FV Leiden and prophylactic 
treatment of women with pregnancy complications like pre-eclampsia, stillbirth, 
or preterm birth is not recommended. However, screening for FV Leiden in 
women with personal or family history of venous thrombosis may be beneficial 
regarding thrombosis prophylaxis in association with future pregnancies.
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In conclusion, maternal carriage of FV Leiden was associated with a strong risk 
for pregnancy-associated deep venous thrombosis, a trend of increased risk for 
pre-eclampsia, and a moderate risk for unexplained stillbirth and preterm birth. 
The results can be generalized to Finnish women with pregnancies continuing 
beyond the first trimester and may be applied to Caucasian women in populations 
with a similar prevalence of FV Leiden and high standard prenatal care.
Figure 4. Association of FV Leiden with pregnancy complications.
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ICD-10 codes from the Hospital Discharge Register
G08 Phlebitis/endophlebitis/thrombophlebitis septica sive thorombosis/embolia 
septica venarum intracranialium/intraspinalium
G45 Ischaemia cerebri transitoria
G45.0-G45.9
G45.3 Amaurosis fugax
G95.1 Myelopathiae vasculares (infarctus medullae spinalis acutus, thrombosis 
arterialis medullae spinalis, thrombosis/thrombophlebitis intraspinalis non 
pyogenes)




I21 Infarctus myocardii acutus
I21.0-I21.99




I51.3 Thrombosis intracardialis non alibi classificata
I63 Infarctus cerebri
I63.0-I63.9
I63.6 Infarctus (non pyogenes) cerebri e thrombosi venorum cerebralium
I65 Occlusio sive stenosis arteriarum praecerebralium sine infarctu cerebri
I65.0-I65.9
I66 Occlusio sive stenosis arteriarum cerebralium sine infarctu
I66.0-I66.9
I67.6 Thrombosis non pyogenes systematis venosi intracranialis
I74 Embolia/thrombosis arterialis
I74.0-I74.9
I80 Phlebitis et thrombophlebitis
I80.0-I80.9 Phlebitis/thrombophlebitis venarum superficialium membrorum inferiorum/ 
venae femoralis/ venae iliacae/ venarum profundarum membrorum 
inferiorum/ membri inferioris non specificata/ aliis locis specificatis/ loco non 
specificato)
I81 Thrombosis venae portae
68
I82 Embolia/thrombosis aliarum venarum
I82.0-I82.9 Syndroma Budd-Chiari, thrombophlebitis migrans, embolia/thrombosis 
venae cavae superioris/ venae cavae inferioris/ venae cavae/ venae renalis/ 
venae subclaviae/ aliarum venarum specificatarum/ venae non specificatae)
K55.0 Morbositates vasculares intestini acutae (embolia/thrombosis arteriae/venae 
mesentericae superioris/inferioris) 
N28.0 Ischaemia renis (embolia/thrombosis arteriae renalis)
O03 Abortus spontaneus
O03.0-O03.9
O06 Abortus non specificatus
O06.0-O06.9
O08.2 Embolia post abortum sive graviditatem extrauterinam sive molam 
hydatidosam (Embolia pulmonalis)
O08.7 Aliae complicationes venosae post abortum sive graviditatem extrauterinam 
sive molam hydatidosam
O14 Hypertensio gestationalis cum proteinuria significanti
O14.0 Prae-eclampsia moderata
O14.1 Prae-eclampsia gravis
O14.9 Prae-eclampsia non specificata
O15 Eclampsia
O15.0 Eclampsia in graviditate
O15.1 Eclampsia inter labores
O15.2 Eclampsia in puerperio
O15.9 Eclampsia tempore non specificata
O22 Complicationes venosae in graviditate
O22.2 Thrombophlebitis superficialis in graviditate
O22.3 Thrombophlebitis profunda in graviditate
O22.5 Thrombosis venae cerebralis in graviditate
O22.8 Aliae complicationes venosae specificatae in graviditate
O22.9 Phlebitis in graviditate NAS
O36.4 Cura matris propter mortem intrauterinam fetus
O36.5 Cura matris propter retardationem crescendi fetus
O60 Partus praematurus
O87 Complicationes venosae in puerperio
O87.0 Thrombophlebitis superficialis in puerperio
O87.1 Thrombophlebitis profunda in puerperio
O87.3 Thrombosis venae cerebralis in puerperio
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O87.9 Complicatio venosa non specificata in puerperio (Phlebitis/thrombosis 
puerperalis NAS)
O88 Embolia obstetrica
O88.2 Embolia thrombotica obstetrica (Embolia pulmonalis obstetrica/puerperalis 
NAS)
O95 Mors obstetrica matris causa non specificata
O96 Mors ex qualibet causa obstetrica occurrens plus quam XLII dies sed minus 
quam unum annum post partum
O99.4 Morbi systematis circulatorii complicantes graviditatem, partum et 
puerperium
O99.5 Morbi systematis respiratorii complicantes graviditatem, partum et 
puerperium
Z37.1 Partus fetus mortuus
Z37.3 Partus fetus mortuus
Z37.4 Partus fetus mortuus
Z37.6 Partus fetus mortuus
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